

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Mesenchymal Stromal Cells to Treat Brain Injury

Ciara C. Tate and Casey C. Case
SanBio, Inc., Mountain View, California
USA

1. Introduction

Brain injury occurs from either a traumatic (mechanical), ischemic (decreased oxygen; accounts for 83% of stroke cases), or hemorrhagic (ruptured blood vessel; accounts for 17% of stroke cases) insult to the brain. Stroke and traumatic brain injury (TBI) are major contributors worldwide to both deaths and persistent disabilities. Stroke is the third leading cause of death (behind heart disease and cancer) in the United States, with 137,000 Americans dying from stroke each year (Heron *et al.*, 2009). Stroke is the leading cause of serious, long-term disability in the United States. Currently, 795,000 people have a stroke each year and 15-30% of survivors have a permanent disability (Roger *et al.*, 2011). Annually, 1.7 million people sustain a TBI in the United States, resulting in 52,000 deaths and over 124,000 permanent disabilities each year (Faul *et al.*, 2010). Annual direct (e.g., medical) and indirect (e.g., loss of productivity) costs to the United States are \$41 billion and \$60 billion for stroke and TBI, respectively (Finkelstein *et al.*, 2006; Roger *et al.*, 2011).

Though the etiology differs between traumatic and ischemic injury, there are many similarities in their pathology (Bramlett & Dietrich, 2004; Leker & Shohami, 2002). The primary insult initiates a cascade of secondary events such as edema, excitotoxicity, and increases in free radicals, which act to spread the injury to surrounding tissue (for reviews of the pathology, see Greve & Zink, 2009 for TBI and Mitsios *et al.*, 2006 for ischemic stroke). Note that ischemia is part of the secondary injury response for TBI (Coles, 2004; Garnett *et al.*, 2001). The brain attempts to repair and regenerate, but depending on such factors as injury severity, age of onset, and prior injuries, these endogenous attempts are often insufficient to restore normal function. A treatment that limits the spread of secondary damage and/or promotes repair and regeneration is needed. Current clinical treatment practices for TBI primarily aim to reduce intracranial pressure in an effort to minimize brain damage caused by swelling. For ischemic stroke, the only FDA-approved treatment is breaking down blood clots with tissue plasminogen activator. However, patients must meet strict criteria for receiving this therapy, including a 4 hour time window and no evidence of the following: bleeding, a severely elevated blood pressure or blood sugar, recent surgery, low platelet count, or end-stage liver or kidney disorders. Numerous pharmacological treatments that seemed promising in animal models have failed in clinical trials (Maas *et al.*, 2010; O'Collins *et al.*, 2006). Patients with brain injury vary widely with respect to demographics, severity of injury, location of injury, and co-morbidity factors making clinical trials challenging. Most treatments previously tested involved pathways that are both deleterious and beneficial, making the dosage and timing critical to not interfere with

normal homeostasis or reparative mechanisms in the brain. Furthermore, these treatments targeted single mechanisms, which may not be enough in light of the multi-faceted pathology. Therapies that currently seem more promising, such as progesterone administration (Wright *et al.*, 2007) and cell transplantation, address multiple pathological events.

2. Mesenchymal stromal cells to treat brain injury

2.1 Mesenchymal stromal cells (MSCs)

Mesenchymal stem cells are multipotent cells that can differentiate into cells of the mesoderm germ layer. These cells can be isolated from adipose tissue, amniotic fluid, placenta and umbilical cord, though are most commonly and efficiently derived from adult bone marrow. Marrow-derived cells that adhere to tissue-culture plastic *in vitro* are a heterogeneous population of cells that contain mesenchymal stem cells, but the entire population is more correctly defined as mesenchymal stromal cells (Horwitz *et al.*, 2005). As we learn more about these cell populations, the terminology evolves and the acronym MSC is used (and sometimes misused) for mesenchymal stem cell, mesenchymal stromal cell, multipotent stromal cell, and marrow stromal cell. For the purposes of this chapter, we will not distinguish amongst these cell populations and use MSC as a general acronym.

2.2 Using MSCs to treat brain injury

MSCs are an attractive cell source for transplantation because they are relatively easy to obtain, expand, and manipulate *in vitro*. In addition, adult human MSCs do not have the tumorigenicity risks that pluripotent cells carry. Ample preclinical data demonstrate that MSC transplantation promotes functional recovery following experimental cerebral ischemic or TBI (for review, see Li & Chopp, 2009 or Parr *et al.*, 2007). Autologous MSC therapy has already shown promise for treating clinical stroke (Battistella *et al.*, 2011; Honmou *et al.*, 2011; Lee *et al.*, 2010; Suarez-Monteagudo *et al.*, 2009) and TBI (Cox *et al.*, 2011; Zhang *et al.*, 2008). Collectively, these trials demonstrate that transplanting MSCs either intra-arterially, intravenously, or intracerebrally is safe and no cell-related adverse events were reported. These groups also indicate that some patients receiving MSCs had improved functional outcome; however, these hints at efficacy must be cautiously interpreted because these were primarily safety trials and were not designed to show robust efficacy.

Important considerations for using MSCs in the clinic include timing (acute versus chronic), delivery route (most commonly intravenous, intra-arterial, or intracerebral), and donor source (autologous versus allogeneic). There are advantages and disadvantages for each of these issues, which are outlined in Table 1. According to www.clinicaltrials.gov (searched in August 2011; summarized in Table 2), there are 11 ongoing clinical trials worldwide using MSCs (either primary or derivatives) to treat stroke. Of these 11 studies, 5 are using autologous MSCs and the other 6 are using allogeneic MSCs from either bone marrow, placenta (1 study) or umbilical cord (1 study). Two of the trials are injecting cells directly into the injured brain (either into the injury cavity or the peri-infarct tissue), 1 trial is injecting cells into the carotid artery, and the other 8 are injecting MSCs intravenously. With regard to timing, 2 of the trials are delivering the cells during the acute phase (within 72

hours post-stroke), 7 trials during the sub-acute phase (between 4 days and 6 weeks post-stroke), and 2 studies are delivering cells during the chronic phase (over 6 months post-stroke). As trials more definitively reveal that MSCs transplantation is both safe and effective for treating brain injury in humans, issues of delivery timing and route and donor source, as well as dosage and the use of immunosuppression will need to be more carefully compared.

Issue	Options	Advantages	Disadvantages
Timing	Acute phase	supports neuroprotection	volatile environment strict timing may limit availability
		Chronic phase	supports regeneration easier to distinguish between effects of cell therapy and normal recovery targets larger patient population
	Delivery		Intravenous or Intra-arterial
cells home to site of injury		requires high cell numbers possible systemic effects	
		requires blood brain barrier permeability (thus limits time window)	
Intracerebral		cells placed at site of injury	more invasive extent and location of injury is variable
Donor Source	Autologous	immunocompatible	patients undergo additional procedures
	Allogeneic	MSCs are immunoprivileged	may require immunosuppression
		more cost-effective	requires storage of cell product
		better for repeat dosing	
		off-the-shelf treatment	
cells can be manipulated <i>ex vivo</i> without treatment delays			

Table 1. Clinical considerations for using MSCs to treat brain injury

Sponsor	Country	Start Date	Phase	# Px	Donor	Cell Description	Route	Timing (post-stroke)	Follow-up	clinicaltrials.gov ID
National Cardiovascular Center	Japan	2008-May	I/IIa	12	Auto	Bone marrow mononuclear cells	IV	7-10 days	30 days	NCT01028794
CellMed AG, a subsidiary of BTG plc.	Germany	2008-October	I/II	20	Allo	GLP-1 CellBeads: alginate microcapsules with mesenchymal cells transfected to secrete glucagon like peptide-1	IC	acute	6 months	NCT01298830
University of Texas Health Science Center	USA	2009-January	I	30	Auto	Bone marrow mononuclear cells	IV	24-72 hours	5 years	NCT00859014
University of California, Irvine	USA	2010-January	I	33	Auto	Bone marrow mononuclear cells OR Cultured marrow mesenchymal stromal cells	IV	Mononuclear: 4 days; Mesenchymal: 23 days	90 days	NCT00908856
University Hospital, Grenoble	France	2010-August	II	30	Auto	Mesenchymal stem cells	IV	Up to 6 weeks	24 months	NCT00875654
Stempeutics Research Pvt. Ltd.	Malaysia	2010-December	I/II	78	Allo	Cultured adult mesenchymal stem cells	IV	Up to 10 days	12 months	NCT01091701
SanBio, Inc.	USA	2011-January	I/IIa	18	Allo	SB623: modified marrow stromal cells	IC	6-24 months	24 months	NCT01287936
Stemmedica Cell Technologies, Inc.	USA	2011-February	I/II	35	Allo	Adult mesenchymal bone marrow stem cells	IV	Beyond 6 months	12 months	NCT01297413
Celgene Corporation	USA	2011-March	IIa	44	Allo	Human placenta-derived cells PDA001- (cenplacel-L)	IV	1 OR 1 and 8 days	24 months	NCT01310114
Aldagen	USA	2011-March	II	100	Auto	ALD-401: derived from bone marrow	IA	13-19 days	12 months	NCT01273337
General Hospital of Chinese Armed Police Forces	China	2011-April	II	120	Allo	Umbilical cord mesenchymal stem cells	IV	1st TP: 10-21 days (hemorrhage) OR 7-24 days (ischemic); 2nd TP: lumbar puncture 7d after 1st TP	12 months	NCT01389453

Px= planned number of patients to enroll; Auto=autologous; Allo=allogeneic; IV=intravenously; IC=intracerebral (cavity or peri-infarct tissue); IA=intra-arterial (carotid); TP=transplant

Table 2. Ongoing clinical trials for using MSCs to treat stroke

3. Mechanisms of action underlying beneficial effects

Transplanting stem cells is attractive because they can potentially differentiate into multiple cell types and replace cells lost to injury or disease. MSCs normally give rise to cells along the mesodermal lineage (including bone, cartilage, and adipose tissue); however, there are reports suggesting that they can transdifferentiate into neural cells in certain *in vitro* (Sanchez-Ramos *et al.*, 2000; Woodbury *et al.*, 2000) and *in vivo* (Kopen *et al.*, 1999; Munoz-Elias *et al.*, 2004) environments. Though some studies show a small percentage of donor MSCs express neuronal markers in the injured brain, there is little evidence that these cells functionally incorporate into the endogenous neuronal circuitry. In fact, there is a decidedly lack of evidence that neuronal replacement is the primary mechanism of action for MSC therapy; moreover, there are data demonstrating artifacts associated with MSC to neuron transdifferentiation (Barnabe *et al.*, 2009; Lu *et al.*, 2004; Neuhuber *et al.*, 2004; Phinney & Prockop, 2007; Wells, 2002). There is also the possibility that MSCs replace supporting glial cells (astrocytes, oligodendrocytes, or microglia), which outnumber neurons 10:1 in the brain (reviewed in Boucherie & Hermans, 2009). However, ample evidence shows that benefits and functional recovery occur rapidly and persist long after the donor cells are gone, indicating permanent cell replacement is not required. The most likely governing mechanism is that MSCs provide trophic support to the injured brain, which augments endogenous repair and regeneration pathways. Trophic support, by definition, acts through secreted molecules called trophic factors. MSCs may act as mini-pumps delivering beneficial factors to their microenvironment. Using cells as pumps is preferred to actual engineered pumps because they can deliver a plethora of factors at the site of injury in physiologic concentrations and also respond to the needs of the injured tissue with appropriate feedback. Trophic factors can either directly or indirectly (via a mediator cell) promote neuroprotection (enhance cell survival through repair) or neuroregeneration. MSCs also secrete factors that augment angiogenesis – another important aspect of regeneration after brain injury. An additional likely mechanism of action contributing to the benefit of MSCs is immunosuppression. MSCs can affect immune cells via secreted factors, which would fall under trophic support. For the purposes of this chapter, we will treat it as a separate category since targeting immune functions indirectly promotes recovery compared to acting directly on neural or vascular cells. There is a great deal of overlap between these functions and these categories are fluid. Figure 1 summarizes hypothesized mechanisms of action for MSCs in the injured brain, which are mediated by secreted factors and direct cell-cell contacts.

3.1 Terminology

Trophic support classically means to provide nutrition, but the definition has been expanded to include promoting cellular growth, survival, differentiation, or migration. Similarly, the terms “trophic factor” and “growth factor” have also become more inclusive. Neurotrophic factors are trophic factors acting specifically on neural cells, i.e., promoting the growth, survival, differentiation, or migration of primarily neurons, but also glial cells (astrocytes, oligodendrocytes, microglia and Schwann cells). The name neurotrophin is sometimes used synonymously with neurotrophic factor; however neurotrophins specify a family of four structurally-related proteins: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). The

term cytokines was initially used to distinguish factors that had specific immunomodulatory properties (produced by and act on immune cells), such as interleukins, lymphokines, and interferons. However, it is now known that many classic cytokines are also produced by and act on non-immune cells. Chemokines are a subclass of cytokines that promote chemotaxis (cell movement in response to a chemical concentration gradient). In general, as more functions are discovered about these proteins, definitions and classifications broaden and the terms are often used interchangeably. While trophic factors commonly refer to soluble proteins, extracellular matrix (ECM) proteins that are immobilized in the intercellular space also fall into this category since they direct cell growth, survival, differentiation, and migration.




Fig. 1. Summary of likely mechanisms of action for MSCs in the injured brain, highlighting the interconnectivity.

3.2 Trophic support

Transplanted MSCs augment host repair and recovery primarily through direct and indirect trophic support. MSCs secrete a plethora of factors that are known to promote neural cell survival and regeneration through paracrine signaling to neural, vascular, and immune cells. An overview of relevant trophic factors found to be secreted by human bone marrow-derived MSCs *in vitro* is provided in Table 3. Which of these factors are secreted in the injured brain is under current investigation. Research is also ongoing to determine the exact or even the most critical mechanism(s) governing the beneficial effects of MSC transplantation. For now, we make a leap of knowledge based on existing evidence. There are numerous studies demonstrating that transplanted MSCs promote certain aspects of

Reference	Detection Method	Trophic Factors Found	Abbreviation
(Haynesworth <i>et al.</i> , 1996)	ELISA of Conditioned Medium	Granulocyte colony stimulating factor	G-CSF
		Granulocyte-macrophage colony stimulating factor	GM-CSF
		Interleukin-11	IL-11
		Interleukin-6	IL-6
		Leukemia inhibitory factor	LIF
		Macrophage colony stimulating factor	M-CSF
		Stem cell factor	SCF
(Potian <i>et al.</i> , 2003)	Cytokine Array of Conditioned Medium	Angiogenin	Angiogenin
		Granulocyte colony stimulating factor	G-CSF
		Granulocyte-macrophage colony stimulating factor	GM-CSF
		Growth related oncogene- α	GRO α
		Interleukin-6	IL-6
		Interleukin-8	IL-8
		Monocyte chemoattractant protein-1	MCP-1
		Oncostatin M	OSM
		Transforming growth factor- β	TGF β
(Kinnaird <i>et al.</i> , 2004)	ELISA or Immunoblotting of Conditioned Medium	Angiopoietin-1	ANG-1
		Fibroblast growth factor-2	FGF-2
		Interleukin-6	IL-6
		Monocyte chemoattractant protein-1	MCP-1
		Platelet derived growth factor	PDGF
		Placental growth factor	PIGF
		Vascular endothelial growth factor-A	VEGF-A
(Arnhold <i>et al.</i> , 2006)	ELISA of Conditioned Medium	Brain derived neurotrophic factor	BDNF
		Glial cell line-derived neurotrophic factor	GDNF
		Nerve growth factor	NGF
(Crigler <i>et al.</i> , 2006)	ELISA of Conditioned Medium	Brain derived neurotrophic factor	BDNF
		Interleukin-11	IL-11
		Nerve growth factor	NGF
		Stromal derived factor-1	SDF-1
(Wang <i>et al.</i> , 2006)	ELISA of Conditioned Medium	Hepatocyte growth factor	HGF
		Insulin-like growth factor-1	IGF-1
		Vascular endothelial growth factor	VEGF

Reference	Detection Method	Trophic Factors Found	Abbreviation
(Potapova <i>et al.</i> , 2007)	ELISA of Conditioned Medium	Angiogenin	Angiogenin
		Bone morphogenetic protein-2	BMP-2
		Interleukin-6	IL-6
		Interleukin-8	IL-8
		Interleukin-11	IL-11
		Monocyte chemoattractant protein-1	MCP-1
		Vascular endothelial growth factor	VEGF
(Schinkothe <i>et al.</i> , 2008)	Cytokine Array of Conditioned Medium	Angiopoietin-2	ANG-2
		Fibroblast growth factor-4	FGF-4
		Fibroblast growth factor-9	FGF-9
		Granulocyte colony stimulating factor	G-CSF
		Growth related oncogene	GRO
		Hepatocyte growth factor	HGF
		Interleukin-8	IL-8
		Interleukin-11	IL-11
		Interleukin-17	IL-17
		Monocyte chemoattractant protein-1	MCP-1
		Neurotrophin-4/5	NT-4/5
		Oncostatin M	OSM
		Placental growth factor	PlGF
		Tissue inhibitors of metalloproteinase-1	TIMP-1
		Vascular endothelial growth factor	VEGF
Bone morphogenetic protein-4	BMP-4		
(Tate <i>et al.</i> , 2010)	Cytokine Array of Conditioned Medium	Bone morphogenetic protein-7	BMP-7
		Dickkopf-1	DKK-1
		Fibroblast growth factor-7	FGF-7
		Heparin-binding epidermal growth factor-like growth factor	HB-EGF
		Hepatocyte growth factor	HGF
		Interleukin-6	IL-6
		Monocyte chemoattractant protein-1	MCP-1
		Platelet derived growth factor-AA	PDGF-AA
		Vascular endothelial growth factor	VEGF
		Collagen I	Collagen I
(Lai <i>et al.</i> , 2010)	Immunofluorescence of Extracellular Matrix	Decorin	Decorin
		Fibronectin	Fibronectin
		Laminin	Laminin
		Perlecan	Perlecan

Table 3. Factors secreted *in vitro* by human bone marrow MSCs that may affect neural recovery.

recovery (e.g., decrease apoptosis, increase neurogenesis, synaptogenesis, and angiogenesis) in the injured brain. Concurrently, there are other studies showing that factors known to be secreted by MSCs are involved in mechanisms that promote these same aspects of recovery. The assumption is that some combination of these pro-recovery mechanisms occurs when MSCs are transplanted into the injured brain and that MSC-secreted factors are essential for these effects. Table 4 reviews potential beneficial mechanisms of action for repair and regeneration of the injured brain provided by MSC-secreted factors. The table provides references that demonstrate that the protein of interest enhances either 1) neuroprotection, 2) neural stem/progenitor cell proliferation or migration, 3) neural stem/progenitor cell differentiation, 4) neuritegenesis or synaptogenesis, 5) angiogenesis, or 6) another mechanism involved in recovery (such as reducing inhibitory components of the glial scar). While these entries are based on a thorough search, it is not intended to be completely exhaustive. Also, only the beneficial aspects of the various growth factors are presented. Some factors that enhance one pathway act as inhibitors in another (e.g., the pro-inflammatory molecule interleukin-17 potentiates neuronal cell death but supports angiogenesis). Since these studies often examine pathways individually, it is not clear which are the primary mechanisms that occur when (if) the molecule is secreted by MSCs in the injured brain. Further, the exact timing and concentration of the trophic factor are likely critical in determining to which pathways they contribute.

		Neuro-protection (↓Apoptosis)	Promotes Neuroregeneration			↑ Angiogenesis	Additional
			↑ NSC Proliferation or Migration	↑ NSC Differentiation	↑ Neurite Outgrowth or Synapse Formation		
Soluble Growth Factors	Angiogenin					(*Distler <i>et al.</i> , 2003)	
	ANG-1	(*Hansen <i>et al.</i> , 2008)	(*Ohab & Carmichael, 2008)		(*Hansen <i>et al.</i> , 2008)	(*Distler <i>et al.</i> , 2003)	Restore BBB (Nag <i>et al.</i> , 2011)
	ANG-2		(Liu <i>et al.</i> , 2009)	neuronal (Liu <i>et al.</i> , 2009)		in presence of VEGF (*Distler <i>et al.</i> , 2003)	
	BDNF	(*Lykissas <i>et al.</i> , 2007)	(*Bath & Lee, 2010; *Schabitz <i>et al.</i> , 2007)	neuronal (*Bath & Lee, 2010)	(Gascon <i>et al.</i> , 2005; *Lipsky & Marini, 2007; *Lykissas <i>et al.</i> , 2007)	(Qin <i>et al.</i> , 2011)	
	BMP-2	(Iantosca <i>et al.</i> , 1999)		astrocytic (*Sabo <i>et al.</i> , 2009)	(Gratacos <i>et al.</i> , 2001)		
	BMP-4	(Iantosca <i>et al.</i> , 1999)		astrocytic (*Sabo <i>et al.</i> , 2009)			
	BMP-7	(Yabe <i>et al.</i> , 2002)	(Chou <i>et al.</i> , 2006)	astrocytic (Gajavelli <i>et al.</i> , 2004)			

	Neuro-protection (↓Apoptosis)	Promotes Neuroregeneration			↑Angiogenesis	Additional
		↑ NSC Proliferation or Migration	↑ NSC Differentiation	↑ Neurite Outgrowth or Synapse Formation		
DKK-1				(Endo <i>et al.</i> , 2008)	(Smadja <i>et al.</i> , 2010)	
FGF-2	(*Alzheimer & Werner, 2002; *Zechel <i>et al.</i> , 2010)	(*Mudo <i>et al.</i> , 2009; *Zechel <i>et al.</i> , 2010)	(*Mudo <i>et al.</i> , 2009; *Zechel <i>et al.</i> , 2010)	(*Zechel <i>et al.</i> , 2010)	(*Distler <i>et al.</i> , 2003; Kumar <i>et al.</i> , 1998)	↑MSC homing (Schmidt <i>et al.</i> , 2006); Restore BBB (Bendfeldt <i>et al.</i> , 2007)
FGF-4		(Kosaka <i>et al.</i> , 2006)	neuronal (Kosaka <i>et al.</i> , 2006)		(*Fan & Yang, 2007)	
FGF-7	(Sadohara <i>et al.</i> , 2001)			(Terauchi <i>et al.</i> , 2010)	(Gillis <i>et al.</i> , 1999)	
FGF-9	(Lum <i>et al.</i> , 2009)	(Lum <i>et al.</i> , 2009)	neuronal (Lum <i>et al.</i> , 2009)		(Frontini <i>et al.</i> , 2011)	
G-CSF	(Schabitz <i>et al.</i> , 2003; Schneider <i>et al.</i> , 2005; Sehara <i>et al.</i> , 2007; Solaroglu <i>et al.</i> , 2006)	(Schneider <i>et al.</i> , 2005; Shyu <i>et al.</i> , 2004)	neuronal (Schneider <i>et al.</i> , 2005)		(Minamino <i>et al.</i> , 2005; Sehara <i>et al.</i> , 2007)	↑MSC homing (Deng <i>et al.</i> , 2011)
GM-CSF	(Huang <i>et al.</i> , 2007)			(Bouhy <i>et al.</i> , 2006)	(Buschmann <i>et al.</i> , 2003)	
GDNF	(Lu <i>et al.</i> , 2005; Shang <i>et al.</i> , 2011; Shirakura <i>et al.</i> , 2004)	(Dempsey <i>et al.</i> , 2003)		(Shirakura <i>et al.</i> , 2004)		
GRO α			oligodendrocytic (Robinson <i>et al.</i> , 1998)		(Bechara <i>et al.</i> , 2007)	
HB-EGF	(Opanashuk <i>et al.</i> , 1999)	(Jin <i>et al.</i> , 2002)	neuronal (Jin <i>et al.</i> , 2004) and glial (Korblum 1999)			
HGF	(Honda <i>et al.</i> , 1995; Shang <i>et al.</i> , 2011)	(Shang <i>et al.</i> , 2011)	neuronal and glial (Shang <i>et al.</i> , 2011)	(Hamanoue <i>et al.</i> , 1996; Shang <i>et al.</i> , 2011; Shimamura <i>et al.</i> , 2006)	(*Distler <i>et al.</i> , 2003; Shang <i>et al.</i> , 2011; Shimamura <i>et al.</i> , 2006)	↑ MSC homing (Neuss <i>et al.</i> , 2004; Ponte <i>et al.</i> , 2007; Son <i>et al.</i> , 2006); ↓ glial scar (Shang <i>et al.</i> , 2011; Shimamura <i>et al.</i> , 2006)

		Neuro-protection (↓Apoptosis)	Promotes Neuroregeneration			↑Angiogenesis	Additional
			↑ NSC Proliferation or Migration	↑ NSC Differentiation	↑ Neurite Outgrowth or Synapse Formation		
IGF-1	(Wilkins <i>et al.</i> , 2001; Yamada <i>et al.</i> , 2001)	(Dempsey <i>et al.</i> , 2003; *Joseph D'Ercole & Ye, 2008)	neuronal and glial (*Joseph D'Ercole & Ye, 2008)	(*Joseph D'Ercole & Ye, 2008)	(*Distler <i>et al.</i> , 2003; Lopez-Lopez <i>et al.</i> , 2004)	↑MSC homing (Ponte <i>et al.</i> , 2007)	
IL-6	(Swartz <i>et al.</i> , 2001)		neuronal (Oh <i>et al.</i> , 2010) and astrocytic (Taga & Fukuda, 2005)	(Oh <i>et al.</i> , 2010)	(*Fan & Yang, 2007)		
IL-8	(Araujo & Cotman, 1993)				(*Fan & Yang, 2007)	↑MSC homing (Wang <i>et al.</i> , 2002)	
IL-11			neuronal (Mehler <i>et al.</i> , 1993)				
IL-17					(Numasaki <i>et al.</i> , 2003)		
LIF	(Nobes & Tolkovsky, 1995)	(Bauer <i>et al.</i> , 2003; Shimazaki <i>et al.</i> , 2001)		(Blesch <i>et al.</i> , 1999)		↑cell homing (Sugiura <i>et al.</i> , 2000)	
MCP-1		(Widera <i>et al.</i> , 2004; Yan <i>et al.</i> , 2007)				↑MSC homing (Wang <i>et al.</i> , 2002)	
M-CSF	(Vincent <i>et al.</i> , 2002)				(Minamino <i>et al.</i> , 2005)		
NGF	(*Lykissas <i>et al.</i> , 2007; Shirakura <i>et al.</i> , 2004)		neuronal (Yung <i>et al.</i> , 2010; Zhu <i>et al.</i> , 2011)	(Gascon <i>et al.</i> , 2005; *Lykissas <i>et al.</i> , 2007)	(*Lazarovici <i>et al.</i> , 2006)		
NT-4/5	(*Lykissas <i>et al.</i> , 2007)		neuronal (Shen <i>et al.</i> , 2010)	(*Lykissas <i>et al.</i> , 2007)			
OSM	(Weiss <i>et al.</i> , 2006)		oligoendrocytic (Glezer & Rivest, 2010)		(Vasse <i>et al.</i> , 1999)		
PDGF	(Iihara <i>et al.</i> , 1997; Vana <i>et al.</i> , 2007)	(Forsberg- Nilsson <i>et al.</i> , 1998)	neuronal (Johe <i>et al.</i> , 1996)		(*Beck & Plate, 2009; *Fan & Yang, 2007)	↑MSC homing (Ponte <i>et al.</i> , 2007)	
PIGF	(Du <i>et al.</i> , 2010)				(*Beck & Plate, 2009)		

		Neuro-protection (↓Apoptosis)	Promotes Neuroregeneration			↑Angiogenesis	Additional
			↑ NSC Proliferation or Migration	↑ NSC Differentiation	↑ Neurite Outgrowth or Synapse Formation		
	SCF	(Dhandapani <i>et al.</i> , 2005; Erlandsson <i>et al.</i> , 2004; Li <i>et al.</i> , 2009)	(Bantubungi <i>et al.</i> , 2008; Erlandsson <i>et al.</i> , 2004; Zhao <i>et al.</i> , 2007)			(Sun <i>et al.</i> , 2006)	↑MSC homing (Bantubungi <i>et al.</i> , 2008; Erlandsson <i>et al.</i> , 2004)
	SDF-1		(*Ohab & Carmichael, 2008; Thored <i>et al.</i> , 2006)				↑ MSC homing (Ponte <i>et al.</i> , 2007; Son <i>et al.</i> , 2006) and survival (Kortessidis <i>et al.</i> , 2005)
	TGFβ	(*Buisson <i>et al.</i> , 2003; Lu <i>et al.</i> , 2005)	(Ma <i>et al.</i> , 2008; Mathieu <i>et al.</i> , 2010)		(Yi <i>et al.</i> , 2010)	(*Beck & Plate, 2009; *Fan & Yang, 2007)	
	TIMP-1	(Tan <i>et al.</i> , 2003)					
	VEGF	(Jin <i>et al.</i> , 2000; Sun <i>et al.</i> , 2003)	(Sun <i>et al.</i> , 2003; Wang <i>et al.</i> , 2007a; Wang <i>et al.</i> , 2007b)		(Erskine <i>et al.</i> , 2011; Jin <i>et al.</i> , 2006)	(*Greenberg & Jin, 2005; *Shibuya, 2009)	
Matrix Proteins	Collagen I		(Ma <i>et al.</i> , 2004)	neuronal (Ma <i>et al.</i> , 2004)		(*Sottile, 2004)	
	Decorin				(Davies <i>et al.</i> , 2004)		↓ glial scar (Davies <i>et al.</i> , 2004)
	Fibronectin	(Sakai <i>et al.</i> , 2001; Tate <i>et al.</i> , 2007)	(*Henderson & Copp, 1997; Tate <i>et al.</i> , 2004; Testaz & Duband, 2001)	oligodendrocytic (Hu <i>et al.</i> , 2009)	(Einheber <i>et al.</i> , 1996; *Pires Neto <i>et al.</i> , 1999)	(*Sottile, 2004)	
	Laminin	(Hall <i>et al.</i> , 2008)	(Hall <i>et al.</i> , 2008; *Perris & Perissinotto, 2000; Tate <i>et al.</i> , 2004)	neuronal (Boote Jones & Mallapragada, 2007; Tate <i>et al.</i> , 2004)	(*Colognato and Yurchenco, 2000; *Pires-Neto 1999)	(*Sottile, 2004)	Restore BBB (Hunter <i>et al.</i> , 1992); ↓glial scar (Hou <i>et al.</i> , 2005)
	Perlecan	(*Bix & Iozzo, 2008; Lee <i>et al.</i> , 2011)				(*Bix & Iozzo, 2008; Lee <i>et al.</i> , 2011)	

*Indicates review article; NSC=Neural stem/progenitor cell; Growth factor abbreviations are defined in Table 3

Table 4. Evidence of MSC-secreted factors promoting neuroprotection or regeneration.

3.2.1 Neuroprotection

Following the initial insult, secondary injury mechanisms persist and cause cell death to surrounding tissue. While the initial ischemic or mechanical insult causes immediate necrotic death, secondary cell death primarily occurs through apoptosis. MSCs secrete multiple factors known to promote neural cell survival (see Table 4). Human MSCs have been shown to rescue neural cells following *in vitro* injury (e.g., oxygen glucose deprivation, glutamate toxicity) via secreted soluble factors (Tate *et al.*, 2010; Zhong *et al.*, 2003) and ECM proteins (Aizman *et al.*, 2009). There are several reports of decreased apoptotic markers and enhanced preservation of neural cells in the injury penumbra when transplanting MSCs following experimental ischemic stroke (Li *et al.*, 2010; Li *et al.*, 2002; Xin *et al.*, 2010) or TBI (Kim *et al.*, 2010; Xiong *et al.*, 2009). For example, delivering human MSCs intravenously 1 day following experimental cerebral ischemia in rats led to significant reduction in apoptotic cell death in the injury penumbra as well as functional behavioral recovery (Li *et al.*, 2002). This study also found an increase in BDNF and NGF in the ipsilateral hemisphere of MSC-treated rats at 7 days post-stroke; however, they did not distinguish whether these trophic factors were produced by the donor or host cells. Li *et al.* (2010) show that transplanting human MSCs into the injury penumbra 1 week following experimental cerebral ischemia in monkeys decreased apoptotic cell death and the lesion volume. Human MSCs transplanted into the injury cavity 1 week following experimental TBI in rats lead to enhanced cell survival in the hippocampus and improved functional recovery, and this was further improved when the MSCs were delivered within a collagen I scaffold (Xiong *et al.*, 2009). Kim *et al.* (2010) found that delivering human MSCs intravenously 1 day post-TBI in rats improved functional recovery and enhanced host cell survival by increasing pAkt and decreasing caspase-3 cleavage. Further, this group reports increases in BDNF, NGF, and NT-3 in the MSC-treated brains, though they did not distinguish between donor or host origin. Clearly, exogenous MSCs provide neuroprotection following brain injury and this is one probable mechanism of action for their benefit.

3.2.2 Neuroregeneration

After brain injury, the brain attempts to regenerate by resorting to a developmental-like state with increased neurogenesis, neurite outgrowth, synaptogenesis, re-myelination, re-formation of the blood brain barrier, and angiogenesis. Once thought to be unable to regenerate, it is now known that neural stem cells persist in the normal adult brain (neurogenic zones include the subventricular zone in the lateral ventricles and the subgranular zone in the dentate gyrus of the hippocampus). After an ischemic or traumatic injury, endogenous neural stem cells proliferate, migrate to the site of injury, and differentiate into neurons and glia (Kernie & Parent, 2010). Neuroplasticity is the reorganization of neuronal circuitry by changing the number and/or strength of neurites and synapses. Such remapping occurs throughout life for learning and memory formation, and compensatory plasticity occurs in the spared tissue following brain injury (Nishibe *et al.*, 2010). Neuroregeneration collectively includes neural stem/progenitor cell proliferation, migration and differentiation, neurite outgrowth, and synapse formation.

There are multiple *in vitro* studies showing that MSCs direct neuroregenerative processes. Bai *et al.* (2007) show that mouse neural stem cells had increased migration and neuronal and oligodendrocytic differentiation when they were cultured with either human MSCs or MSC-conditioned medium, indicating that soluble proteins are responsible for these effects. In related work, co-culture of human MSCs with rat neural stem cells revealed that MSCs promote differentiation into primarily astrocytes and oligodendrocytes (Robinson *et al.*, 2011). However MSC-conditioned media promoted primarily oligodendrocytic differentiation (Robinson *et al.*, 2011), indicating that matrix components or direct cell-cell contact also account for the effects of MSCs on neural stem cell differentiation. Indeed, Aizman *et al.* (2009) demonstrate that human MSC-derived ECM promotes differentiation of cortical cells into neurons, astrocytes and oligodendrocytes and also enhances neuronal neurite networks compared to single ECM proteins. Transplantation of MSCs augments endogenous regeneration following experimental ischemic stroke (Bao *et al.*, 2011; Li *et al.*, 2010; Li *et al.*, 2002; Xin *et al.*, 2010; Yoo *et al.*, 2008) and TBI (Mahmood *et al.*, 2004; Xiong *et al.*, 2009). For example, both Bao *et al.* (2011) and Yoo *et al.* (2008) show that intracerebral transplantation of human MSCs 3 days following experimental cerebral ischemia in rats increases proliferation and migration of host neural stem cells and also decreases their apoptosis, thus enhancing neurogenesis. They also report enhanced behavioral recovery, and Bao *et al.* demonstrate increases in BDNF, NT-3, and VEGF in the brains of MSC-treated rats, though they do not identify the source of these cytokines. Xin *et al.* (2010) found that intravenous delivery of mouse MSCs 1 day following experimental stroke in mice lead to increases in axon fiber density, synaptogenesis and myelination. Following experimental TBI in rats, transplanted rat MSCs promoted increased proliferation and neuronal differentiation in neurogenic zones along with improved motor and sensory recovery (Mahmood *et al.*, 2004). Xiong *et al.* (2009) also report that transplanting human MSCs intracerebrally 1 week post-TBI in rats leads to increased axonal fiber length and that the fiber length was directly proportional to performance on the behavior tasks. Multiple trophic factors secreted by MSCs may contribute to enhancing neuroregeneration (see Table 4).

The glial scar that forms following brain injury acutely acts to sequester the injury. Cellular components of the glial scar include reactive astrocytes, which help buffer excess glutamate and secrete neurotrophic factors, and activated microglia/macrophages which clear out dead tissue and secrete neurotrophic factors. However, extracellular components of the glial scar that persists adjacent to the injury site have been found to inhibit neurite extension (e.g., neurocan, Nogo protein), thus limiting regeneration (for review, see Properzi *et al.*, 2003). Transplantation of MSCs helps overcome this glial scar limitation following experimental stroke (Li *et al.*, 2010; Li *et al.*, 2005; Pavlichenko *et al.*, 2008; Shen *et al.*, 2008) and TBI (Zanier *et al.*, 2011). Following ischemic stroke, rats treated with rat MSCs transplanted intravenously had decreased glial scar thickness at both the acute (3 and 6 days post-stroke; Pavlichenko *et al.*, 2008) and chronic (4 months post-stroke; Li *et al.*, 2005) phases. Along with decreased glial scar thickness, these studies report decreased lesion volume, enhanced regeneration, and functional recovery for animals treated with MSCs. Shen *et al.* (2008) show a decrease in neurocan (an inhibitory chondroitin sulphate proteoglycan) and enhanced axonal outgrowth in the injury penumbra when ischemic rats were treated with rat MSCs. Zanier *et al.* (2011) transplanted human umbilical cord blood-derived MSCs into the traumatically injured mouse brain and observed a decrease in reactive astrocytes in the glial scar region along with

decreased lesion volume and functional recovery. Collectively, these data illustrate that exogenous MSCs promote neuroregeneration following brain injury by directly affecting neural stem/progenitor cells and neurons and/or by reducing inhibitory glial scar components.

3.2.3 Angiogenesis

Another important aspect of regeneration is angiogenesis, which is the formation of new blood vessels from existing vasculature. In the adult, angiogenesis occurs after injury to help supply the damaged tissue with oxygen and nutrients. The process includes basement membrane disruption, endothelial cell migration and proliferation, three-dimensional tube formation, maturation, and stabilization by vascular smooth muscle cells. Each step is regulated by multiple cytokines and ECM molecules (for review, see Distler *et al.*, 2003 or Fan & Yang 2007). Studies show that MSC-conditioned medium enhances endothelial cell proliferation (Kaigler *et al.*, 2003) and promotes angiogenesis *in vitro* and *in vivo* (Kinnaird *et al.*, 2004). Transplanting MSCs increases angiogenesis following experimental ischemic stroke (Omori *et al.*, 2008; Onda *et al.*, 2008; Pavlichenko *et al.*, 2008) and TBI (Xiong *et al.*, 2009). Potential pro-angiogenic factors secreted by MSCs are provided in Table 4. Notably, there is overlap between factors that promote angiogenesis and neurogenesis/neuritogenesis (reviewed in Emanuelli *et al.*, 2003 and Lazarovici *et al.*, 2006). A unique feature of brain vasculature is the existence of the blood-brain barrier (BBB), formed by astrocyte end-feet surrounding specialized capillary endothelial cells in order to tightly regulate brain homeostasis. After injury, there is increased permeability of the BBB leading to edema (reviewed in Nag *et al.*, 2011). Part of the repair process includes restoring the BBB, and regeneration includes formation of the BBB for new vasculature. Specific MSC-secreted factors such as ANG-1, FGF-2, and laminin may be involved in reforming the BBB following injury.

3.3 Immunomodulation

There is a potent immune response following ischemic and traumatic brain injury. The innate immune response is a part of the normal wound healing process; however, persistent inflammation can become cytotoxic. In addition to interacting with neural and vascular cells, MSCs communicate with immune cells and are now known to be immunosuppressive. Examining the interactions of MSCs with immune cells *in vitro* reveals that MSCs suppress T cell proliferation and activation, inhibit B cell proliferation and IgG production, prevent dendritic cell differentiation and migration, and shift the cytokine secretion profile of dendritic cells, helper T cells, and natural killer cells towards anti-inflammatory (reviewed in Mezey *et al.*, 2010 and Nauta & Fibbe, 2007). Interestingly, studies that separate the MSCs from the immune cells using semi-permeable membranes indicate that soluble factors are critical for these effects. Candidate immunomodulatory factors secreted by MSCs include interleukin-6 (IL-6), transforming growth factor β (TGF β), prostaglandin E₂, hepatocyte growth factor (HGF), indoleamine 2,3-dioxygenase (IDO), and monocyte colony stimulating factor (M-CSF) (reviewed in Mezey *et al.*, 2010 and Nauta & Fibbe, 2007). Moreover, ECM proteins, such as fibronectin, also interact with immune cells (Mosesson, 1984; Nasu-Tada *et al.*, 2005). Since shifting to a less inflammatory environment may facilitate neural repair and

regeneration, immunomodulation is another feasible therapeutic mechanism of action for transplanted MSCs. Note that many immunomodulatory factors also have potential roles for directly promoting neural cell survival and regeneration (see Table 4). Likewise, NGF, the prototypic neurotrophic factor, has been shown to be anti-inflammatory (Villoslada & Genain, 2004). The interaction between angiogenesis and inflammation is also well-documented (for review, see Jackson *et al.*, 1997 or Noonan *et al.*, 2008), which further underscores the complexity and interrelatedness of these recovery mechanisms.

3.4 Challenges of identifying critical factors and mechanisms

Cell transplantation is a dynamic treatment that can target multiple therapeutic mechanisms. Advantages of transplanting cells compared to pharmaceutical treatments include the ability to 1) easily localize the treatment to the affected tissue, 2) supply a variety of trophic factors at physiologic concentrations, 3) persist long enough to alter the microenvironment of the injured brain tissue; and 4) interact with host cells. The beneficial effects of transplanted MSCs have been corroborated *in vitro* and *in vivo* and some potential pathways have been identified as described above. It is probable that a combination of multiple mechanisms of action synergistically contribute to improve functional recovery. While this ability to intervene along multiple pathways is desirable for a robust treatment, it makes identifying key mechanisms and factors challenging. Clarifying critical mechanisms of action would allow for treatments to be optimized to best facilitate these roles. Furthermore, difficulty pinpointing key mechanisms is a hurdle for developing potency assays for the clinical use of MSCs. Potency assays are critical for ranking and qualifying different cell lots on their ability to promote recovery. Another complication for determining potency of cells *ex vivo* is that transplanted cells interact with the host cells via paracrine signaling and possibly direct cell-cell contact. MSCs alter the secretion profile of host neural and immune cells, such as astrocytes and microglia (Gao *et al.*, 2005; Xin *et al.*, 2010), which further acts to promote repair and regeneration. Additionally, the secretion profile of MSCs is a function of the microenvironment and changes in the presence of injured brain tissue (Chen *et al.*, 2002a, 2002b). Thus, there is a complex and dynamic web of players involved in MSC-mediated effects. Ideally, potency assays would be easily reproducible *in vitro* assays, however the interplay between donor cells and the host environment is difficult to model *in vitro*. Elucidating critical aspects of this therapy will be the focus of intense research for years to come.

4. Conclusion

Stroke and TBI are major contributors to death and persistent disability, and treatments that effectively promote repair and regeneration are desired. Cell transplantation is a promising treatment for brain injury, and MSCs are an attractive cell source due to their technical and safety advantages. Pre-clinical *in vivo* data show that transplanting MSCs enhances neuroprotection, promotes regeneration and/or suppresses inflammation. MSCs secrete numerous soluble and insoluble factors that are known to benefit the injured brain, which are likely crucial to the mechanisms of action governing MSC-mediated recovery. MSCs aid injured brain tissue by targeting multiple, non-mutually exclusive pathways, which is an advantage for a potential treatment, but a challenge for elucidating critical mechanisms and factors.

5. References

- Aizman, I., Tate, C.C., McGrogan, M. & Case, C.C. (2009). Extracellular Matrix Produced by Bone Marrow Stromal Cells and by their Derivative, SB623 Cells, Supports Neural Cell Growth. *Journal of Neuroscience Research*, Vol.87, No.14, pp. 3198-3206, ISSN 1097-4547
- Alzheimer, C. & Werner, S. (2002). Fibroblast Growth Factors and Neuroprotection. *Advances in Experimental Medicine and Biology*, Vol.513, pp. 335-351, ISSN 0065-2598
- Araujo, D.M. & Cotman, C.W. (1993). Trophic Effects of Interleukin-4, -7 and -8 on Hippocampal Neuronal Cultures: Potential Involvement of Glial-Derived Factors. *Brain Research*, Vol.600, No.1, pp. 49-55, ISSN 0006-8993
- Arnhold, S., Klein, H., Klinz, F.J., Absenger, Y., Schmidt, A., Schinkothe, T., Brixius, K., Kozlowski, J., Desai, B., Bloch, W. & Addicks, K. (2006). Human Bone Marrow Stroma Cells Display Certain Neural Characteristics and Integrate in the Subventricular Compartment After Injection into the Liquor System. *European Journal of Cell Biology*, Vol.85, No.6, pp. 551-565, ISSN 0171-9335
- Bai, L., Caplan, A., Lennon, D. & Miller, R.H. (2007). Human Mesenchymal Stem Cells Signals Regulate Neural Stem Cell Fate. *Neurochemical Research*, Vol.32, No.2, pp. 353-362, ISSN 0364-3190
- Bantubungi, K., Blum, D., Cuvelier, L., Wislet-Gendebien, S., Rogister, B., Brouillet, E. & Schiffmann, S.N. (2008). Stem Cell Factor and Mesenchymal and Neural Stem Cell Transplantation in a Rat Model of Huntington's Disease. *Molecular and Cellular Neurosciences*, Vol.37, No.3, pp. 454-470, ISSN 1095-9327; 1044-7431
- Bao, X., Wei, J., Feng, M., Lu, S., Li, G., Dou, W., Ma, W., Ma, S., An, Y., Qin, C., Zhao, R.C. & Wang, R. (2011). Transplantation of Human Bone Marrow-Derived Mesenchymal Stem Cells Promotes Behavioral Recovery and Endogenous Neurogenesis After Cerebral Ischemia in Rats. *Brain Research*, Vol.1367, pp. 103-113, ISSN 1872-6240; 0006-8993
- Barnabe, G.F., Schwindt, T.T., Calcagnotto, M.E., Motta, F.L., Martinez, G., Jr, de Oliveira, A.C., Keim, L.M., D'Almeida, V., Mendez-Otero, R. & Mello, L.E. (2009). Chemically-Induced RAT Mesenchymal Stem Cells Adopt Molecular Properties of Neuronal-Like Cells but do Not have Basic Neuronal Functional Properties. *PLoS One*, Vol.4, No.4, pp. e5222, ISSN 1932-6203; 1932-6203
- Bath, K.G. & Lee, F.S. (2010). Neurotrophic Factor Control of Adult SVZ Neurogenesis. *Developmental Neurobiology*, Vol.70, No.5, pp. 339-349, ISSN 1932-846X; 1932-8451
- Battistella, V., de Freitas, G.R., da Fonseca, L.M., Mercante, D., Gutfilen, B., Goldenberg, R.C., Dias, J.V., Kasai-Brunswick, T.H., Wajnberg, E., Rosado-de-Castro, P.H., Alves-Leon, S.V., Mendez-Otero, R. & Andre, C. (2011). Safety of Autologous Bone Marrow Mononuclear Cell Transplantation in Patients with Nonacute Ischemic Stroke. *Regenerative Medicine*, Vol.6, No.1, pp. 45-52, ISSN 1746-076X; 1746-0751
- Bauer, S., Rasika, S., Han, J., Mauduit, C., Raccurt, M., Morel, G., Jourdan, F., Benahmed, M., Moyse, E. & Patterson, P.H. (2003). Leukemia Inhibitory Factor is a Key Signal for Injury-Induced Neurogenesis in the Adult Mouse Olfactory Epithelium. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, Vol.23, No.5, pp. 1792-1803, ISSN 1529-2401; 0270-6474

- Bechara, C., Chai, H., Lin, P.H., Yao, Q. & Chen, C. (2007). Growth Related Oncogene-Alpha (GRO-Alpha): Roles in Atherosclerosis, Angiogenesis and Other Inflammatory Conditions. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, Vol.13, No.6, pp. RA87-90, ISSN 1234-1010
- Beck, H. & Plate, K.H. (2009). Angiogenesis After Cerebral Ischemia. *Acta Neuropathologica*, Vol.117, No.5, pp. 481-496, ISSN 1432-0533; 0001-6322
- Bendfeldt, K., Radojevic, V., Kapfhammer, J. & Nitsch, C. (2007). Basic Fibroblast Growth Factor Modulates Density of Blood Vessels and Preserves Tight Junctions in Organotypic Cortical Cultures of Mice: A New in Vitro Model of the Blood-Brain Barrier. *The Journal of Neuroscience*, Vol.27, No.12, pp. 3260-3267, ISSN 1529-2401; 0270-6474
- Bix, G. & Iozzo, R.V. (2008). Novel Interactions of Perlecan: Unraveling Perlecan's Role in Angiogenesis. *Microscopy Research and Technique*, Vol.71, No.5, pp. 339-348, ISSN 1059-910X
- Boote Jones, E.N. & Mallapragada, S.K. (2007). Directed Growth and Differentiation of Stem Cells Towards Neural Cell Fates using Soluble and Surface-Mediated Cues. *Journal of Biomaterials Science. Polymer Edition*, Vol.18, No.8, pp. 999-1015, ISSN 0920-5063
- Boucherie, C. & Hermans, E. (2009). Adult Stem Cell Therapies for Neurological Disorders: Benefits Beyond Neuronal Replacement? *Journal of Neuroscience Research*, Vol.87, No.7, pp. 1509-1521, ISSN 1097-4547; 0360-4012
- Bouhy, D., Malgrange, B., Multon, S., Poirrier, A.L., Scholtes, F., Schoenen, J. & Franzen, R. (2006). Delayed GM-CSF Treatment Stimulates Axonal Regeneration and Functional Recovery in Paraplegic Rats Via an Increased BDNF Expression by Endogenous Macrophages. *The FASEB Journal*, Vol.20, No.8, pp. 1239-1241, ISSN 1530-6860; 0892-6638
- Bramlett, H.M. & Dietrich, W.D. (2004). Pathophysiology of Cerebral Ischemia and Brain Trauma: Similarities and Differences. *Journal of Cerebral Blood Flow and Metabolism*, Vol.24, No.2, pp. 133-150, ISSN 0271-678X
- Buisson, A., Lesne, S., Docagne, F., Ali, C., Nicole, O., MacKenzie, E.T. & Vivien, D. (2003). Transforming Growth Factor-Beta and Ischemic Brain Injury. *Cellular and Molecular Neurobiology*, Vol.23, No.4-5, pp. 539-550, ISSN 0272-4340
- Buschmann, I.R., Busch, H.J., Mies, G. & Hossmann, K.A. (2003). Therapeutic Induction of Arteriogenesis in Hypoperfused Rat Brain Via Granulocyte-Macrophage Colony-Stimulating Factor. *Circulation*, Vol.108, No.5, pp. 610-615, ISSN 1524-4539; 0009-7322
- Chen, X., Katakowski, M., Li, Y., Lu, D., Wang, L., Zhang, L., Chen, J., Xu, Y., Gautam, S., Mahmood, A. & Chopp, M. (2002a). Human Bone Marrow Stromal Cell Cultures Conditioned by Traumatic Brain Tissue Extracts: Growth Factor Production. *Journal of Neuroscience Research*, Vol.69, No.5, pp. 687-691, ISSN 0360-4012
- Chen, X., Li, Y., Wang, L., Katakowski, M., Zhang, L., Chen, J., Xu, Y., Gautam, S.C. & Chopp, M. (2002b). Ischemic Rat Brain Extracts Induce Human Marrow Stromal Cell Growth Factor Production. *Neuropathology*, Vol.22, No.4, pp. 275-279, ISSN 0919-6544

- Chou, J., Harvey, B.K., Chang, C.F., Shen, H., Morales, M. & Wang, Y. (2006). Neuroregenerative Effects of BMP7 After Stroke in Rats. *Journal of the Neurological Sciences*, Vol.240, No.1-2, pp. 21-29, ISSN 0022-510X
- Coles, J.P. (2004). Regional Ischemia After Head Injury. *Current Opinion in Critical Care*, Vol.10, No.2, pp. 120-125, ISSN 1070-5295
- Cox, C.S., Jr, Baumgartner, J.E., Harting, M.T., Worth, L.L., Walker, P.A., Shah, S.K., Ewing-Cobbs, L., Hasan, K.M., Day, M.C., Lee, D., Jimenez, F. & Gee, A. (2011). Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children. *Neurosurgery*, Vol.68, No.3, pp. 588-600, ISSN 1524-4040; 0148-396X
- Crigler, L., Robey, R.C., Asawachaicharn, A., Gaupp, D. & Phinney, D.G. (2006). Human Mesenchymal Stem Cell Subpopulations Express a Variety of Neuro-Regulatory Molecules and Promote Neuronal Cell Survival and Neuritogenesis. *Experimental Neurology*, Vol.198, No.1, pp. 54-64, ISSN 0014-4886
- Davies, J.E., Tang, X., Denning, J.W., Archibald, S.J. & Davies, S.J. (2004). Decorin Suppresses Neurocan, Brevican, Phosphacan and NG2 Expression and Promotes Axon Growth Across Adult Rat Spinal Cord Injuries. *The European Journal of Neuroscience*, Vol.19, No.5, pp. 1226-1242, ISSN 0953-816X
- Dempsey, R.J., Sailor, K.A., Bowen, K.K., Tureyen, K. & Vemuganti, R. (2003). Stroke-Induced Progenitor Cell Proliferation in Adult Spontaneously Hypertensive Rat Brain: Effect of Exogenous IGF-1 and GDNF. *Journal of Neurochemistry*, Vol.87, No.3, pp. 586-597, ISSN 0022-3042
- Deng, J., Zou, Z.M., Zhou, T.L., Su, Y.P., Ai, G.P., Wang, J.P., Xu, H. & Dong, S.W. (2011). Bone Marrow Mesenchymal Stem Cells can be Mobilized into Peripheral Blood by G-CSF in Vivo and Integrate into Traumatically Injured Cerebral Tissue. *Neurological Sciences*, Vol.32, No.4, pp. 641-651, ISSN 1590-3478; 1590-1874
- Dhandapani, K.M., Wade, F.M., Wakade, C., Mahesh, V.B. & Brann, D.W. (2005). Neuroprotection by Stem Cell Factor in Rat Cortical Neurons Involves AKT and NFkappaB. *Journal of Neurochemistry*, Vol.95, No.1, pp. 9-19, 0022-3042; 0022-3042
- Distler, J.H., Hirth, A., Kurowska-Stolarska, M., Gay, R.E., Gay, S. & Distler, O. (2003). Angiogenic and Angiostatic Factors in the Molecular Control of Angiogenesis. *The Quarterly Journal of Nuclear Medicine*, Vol.47, No.3, pp. 149-161, ISSN 1125-0135
- Du, H., Li, P., Pan, Y., Li, W., Hou, J., Chen, H., Wang, J. & Tang, H. (2010). Vascular Endothelial Growth Factor Signaling Implicated in Neuroprotective Effects of Placental Growth Factor in an in Vitro Ischemic Model. *Brain Research*, Vol.1357, pp. 1-8, ISSN 1872-6240; 0006-8993
- Einheber, S., Schnapp, L.M., Salzer, J.L., Cappiello, Z.B. & Milner, T.A. (1996). Regional and Ultrastructural Distribution of the Alpha 8 Integrin Subunit in Developing and Adult Rat Brain Suggests a Role in Synaptic Function. *Journal of Comparative Neurology*, Vol.370, No.1, pp. 105-34, ISSN 1096-9861; 0021-9967
- Emanuelli, C., Schratzberger, P., Kirchmair, R. & Madeddu, P. (2003). Paracrine Control of Vascularization and Neurogenesis by Neurotrophins. *British Journal of Pharmacology*, Vol.140, No.4, pp. 614-619, ISSN 0007-1188
- Endo, Y., Beauchamp, E., Woods, D., Taylor, W.G., Toretsky, J.A., Uren, A. & Rubin, J.S. (2008). Wnt-3a and Dickkopf-1 Stimulate Neurite Outgrowth in Ewing Tumor Cells

- Via a Frizzled3- and c-Jun N-Terminal Kinase-Dependent Mechanism. *Molecular and Cellular Biology*, Vol.28, No.7, pp. 2368-2379, ISSN 1098-5549; 0270-7306
- Erlandsson, A., Larsson, J. & Forsberg-Nilsson, K. (2004). Stem Cell Factor is a Chemoattractant and a Survival Factor for CNS Stem Cells. *Experimental Cell Research*, Vol.301, No.2, pp. 201-210, ISSN 0014-4827
- Erskine, L., Reijntjes, S., Pratt, T., Denti, L., Schwarz, Q., Vieira, J.M., Alakakone, B., Shewan, D. & Ruhrberg, C. (2011). VEGF Signaling through Neuropilin 1 Guides Commissural Axon Crossing at the Optic Chiasm. *Neuron*, Vol.70, No.5, pp. 951-965, ISSN 1097-4199; 0896-6273
- Fan, Y. & Yang, G.Y. (2007). Therapeutic Angiogenesis for Brain Ischemia: A Brief Review. *Journal of Neuroimmune Pharmacology*, Vol.2, No.3, pp. 284-289, ISSN 1557-1904; 1557-1890
- Faul, M., Xu, L., Wald, M.M. & Coronado, V.G. (2010). *Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths 2002-2006*. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, GA
- Finkelstein EA, Corso PS, Miller TR. 2006. *The Incidence and Economic Burden of Injuries in the United States*. Oxford University Press, New York, NY
- Forsberg-Nilsson, K., Behar, T.N., Afrakhte, M., Barker, J.L. & McKay, R.D. (1998). Platelet-Derived Growth Factor Induces Chemotaxis of Neuroepithelial Stem Cells. *J Neurosci Res*, Vol.53, No.5, pp. 521-530, ISSN 1097-4547; 0360-4012
- Frontini, M.J., Nong, Z., Gros, R., Drangova, M., O'Neil, C., Rahman, M.N., Akawi, O., Yin, H., Ellis, C.G. & Pickering, J.G. (2011). Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. *Nature Biotechnology*, Vol.29, No.5, pp. 421-427, ISSN 1546-1696; 1087-0156
- Gajavelli, S., Wood, P.M., Pennica, D., Whittemore, S.R. & Tsoulfas, P. (2004). BMP Signaling Initiates a Neural Crest Differentiation Program in Embryonic Rat CNS Stem Cells. *Experimental Neurology*, Vol.188, No.2, pp. 205-223, ISSN 0014-4886
- Gao, Q., Li, Y. & Chopp, M. (2005). Bone Marrow Stromal Cells Increase Astrocyte Survival via Upregulation of Phosphoinositide 3-kinase/threonine Protein Kinase and Mitogen-Activated Protein Kinase kinase/extracellular Signal-Regulated Kinase Pathways and Stimulate Astrocyte Trophic Factor Gene Expression After Anaerobic Insult. *Neuroscience*, Vol.136, No.1, pp. 123-134, ISSN 0306-4522
- Garnett, M.R., Blamire, A.M., Corkill, R.G., Rajagopalan, B., Young, J.D., Cadoux-Hudson, T.A. & Styles, P. (2001). Abnormal Cerebral Blood Volume in Regions of Contused and Normal Appearing Brain Following Traumatic Brain Injury using Perfusion Magnetic Resonance Imaging. *Journal of Neurotrauma*, Vol.18, No.6, pp. 585-593, ISSN 0897-7151
- Gascon, E., Vutskits, L., Zhang, H., Barral-Moran, M.J., Kiss, P.J., Mas, C. & Kiss, J.Z. (2005). Sequential Activation of p75 and TrkB is Involved in Dendritic Development of Subventricular Zone-Derived Neuronal Progenitors in Vitro. *The European Journal of Neuroscience*, Vol.21, No.1, pp. 69-80, ISSN 0953-816X
- Gillis, P., Savla, U., Volpert, O.V., Jimenez, B., Waters, C.M., Panos, R.J. & Bouck, N.P. (1999). Keratinocyte Growth Factor Induces Angiogenesis and Protects Endothelial

- Barrier Function. *Journal of Cell Science*, Vol.112, Pt 12, pp. 2049-2057, ISSN 0021-9533
- Glezer, I. & Rivest, S. (2010). Oncostatin M is a Novel Glucocorticoid-Dependent Neuroinflammatory Factor that Enhances Oligodendrocyte Precursor Cell Activity in Demyelinated Sites. *Brain, Behavior, and Immunity*, Vol.24, No.5, pp. 695-704, ISSN 1090-2139; 0889-1591
- Gratacos, E., Checa, N., Perez-Navarro, E. & Alberch, J. (2001). Brain-Derived Neurotrophic Factor (BDNF) Mediates Bone Morphogenetic Protein-2 (BMP-2) Effects on Cultured Striatal Neurons. *Journal of Neurochemistry*, Vol.79, No.4, pp. 747-755, ISSN 0022-3042
- Greenberg, D.A. & Jin, K. (2005). From Angiogenesis to Neuropathology. *Nature*, Vol.438, No.7070, pp. 954-959, ISSN 1476-4687; 0028-0836
- Greve, M.W. & Zink, B.J. (2009). Pathophysiology of Traumatic Brain Injury. *The Mount Sinai Journal of Medicine, New York*, Vol.76, No.2, pp. 97-104, ISSN 1931-7581; 0027-2507
- Hall, P.E., Lathia, J.D., Caldwell, M.A. & Ffrench-Constant, C. (2008). Laminin Enhances the Growth of Human Neural Stem Cells in Defined Culture Media. *BMC Neuroscience*, Vol.9, pp. 71, ISSN 1471-2202
- Hamanoue, M., Takemoto, N., Matsumoto, K., Nakamura, T., Nakajima, K. & Kohsaka, S. (1996). Neurotrophic Effect of Hepatocyte Growth Factor on Central Nervous System Neurons in Vitro. *Journal of Neuroscience Research*, Vol.43, No.5, pp. 554-564, ISSN 0360-4012
- Hansen, T.M., Moss, A.J. & Brindle, N.P. (2008). Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke. *Current Neurovascular Research*, Vol.5, No.4, pp. 236-245, ISSN 1875-5739; 1567-2026
- Haynesworth, S.E., Baber, M.A. & Caplan, A.I. (1996). Cytokine Expression by Human Marrow-Derived Mesenchymal Progenitor Cells in Vitro: Effects of Dexamethasone and IL-1 Alpha. *Journal of Cellular Physiology*, Vol.166, No.3, pp. 585-592, ISSN 0021-9541
- Henderson, D.J. & Copp, A.J. (1997). Role of the Extracellular Matrix in Neural Crest Cell Migration. *Journal of Anatomy*, Vol.191, Pt.4, pp. 507-515, ISSN 1469-7580; 0021-8782
- Heron, M., Hoyert, D.L., Murphy, S.L., Xu, J., Kochanek, K.D. & Tejada-Vera, B. (2009). Deaths: Final Data for 2006. *National Vital Statistics Reports : From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System*, Vol.57, No.14, pp. 1-134, ISSN 1551-8922
- Honda, S., Kagoshima, M., Wanaka, A., Tohyama, M., Matsumoto, K. & Nakamura, T. (1995). Localization and Functional Coupling of HGF and c-Met/HGF Receptor in Rat Brain: Implication as Neurotrophic Factor. *Brain Research.Molecular Brain Research*, Vol.32, No.2, pp. 197-210, ISSN 0169-328X
- Honmou, O., Houkin, K., Matsunaga, T., Niitsu, Y., Ishiai, S., Onodera, R., Waxman, S.G. & Kocsis, J.D. (2011). Intravenous Administration of Auto Serum-Expanded Autologous Mesenchymal Stem Cells in Stroke. *Brain*, Vol.134, No.Pt 6, pp. 1790-1807, ISSN 1460-2156; 0006-8950
- Horwitz, E.M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I., Marini, F.C., Deans, R.J., Krause, D.S., Keating, A. & International Society for Cellular Therapy.

- (2005). Clarification of the Nomenclature for MSC: The International Society for Cellular Therapy Position Statement. *Cytotherapy*, Vol.7, No.5, pp. 393-395, ISSN 1465-3249
- Hou, S., Xu, Q., Tian, W., Cui, F., Cai, Q., Ma, J. & Lee, I.S. (2005). The Repair of Brain Lesion by Implantation of Hyaluronic Acid Hydrogels Modified with Laminin. *Journal of Neuroscience Methods*, Vol.148, No.1, pp. 60-70, ISSN 0165-0270
- Hu, J., Deng, L., Wang, X. & Xu, X.M. (2009). Effects of Extracellular Matrix Molecules on the Growth Properties of Oligodendrocyte Progenitor Cells in Vitro. *Journal of Neuroscience Research*, Vol.87, No.13, pp. 2854-2862, ISSN 1097-4547; 0360-4012
- Huang, X., Choi, J.K., Park, S.R., Ha, Y., Park, H., Yoon, S.H., Park, H.C., Park, J.O. & Choi, B.H. (2007). GM-CSF Inhibits Apoptosis of Neural Cells Via Regulating the Expression of Apoptosis-Related Proteins. *Neuroscience Research*, Vol.58, No.1, pp. 50-57, ISSN 0168-0102
- Hunter, D.D., Llinas, R., Ard, M., Merlie, J.P. & Sanes, J.R. (1992). Expression of s-Laminin and Laminin in the Developing Rat Central Nervous System. *The Journal of Comparative Neurology*, Vol.323, No.2, pp. 238-251, ISSN 0021-9967
- Iantosca, M.R., McPherson, C.E., Ho, S.Y. & Maxwell, G.D. (1999). Bone Morphogenetic Proteins-2 and -4 Attenuate Apoptosis in a Cerebellar Primitive Neuroectodermal Tumor Cell Line. *Journal of Neuroscience Research*, Vol.56, No.3, pp. 248-258, ISSN 0360-4012
- Iihara, K., Hashimoto, N., Tsukahara, T., Sakata, M., Yanamoto, H. & Taniguchi, T. (1997). Platelet-Derived Growth Factor-BB, but Not -AA, Prevents Delayed Neuronal Death After Forebrain Ischemia in Rats. *Journal of Cerebral Blood Flow and Metabolism*, Vol.17, No.10, pp. 1097-1106, ISSN 0271-678X
- Jackson, J.R., Seed, M.P., Kircher, C.H., Willoughby, D.A. & Winkler, J.D. (1997). The Codependence of Angiogenesis and Chronic Inflammation. *The FASEB Journal*, Vol.11, No.6, pp. 457-465, ISSN 0892-6638
- Jin, K., Mao, X.O. & Greenberg, D.A. (2006). Vascular Endothelial Growth Factor Stimulates Neurite Outgrowth from Cerebral Cortical Neurons Via Rho Kinase Signaling. *Journal of Neurobiology*, Vol.66, No.3, pp. 236-242, ISSN 0022-3034
- Jin, K., Mao, X.O., Sun, Y., Xie, L., Jin, L., Nishi, E., Klagsbrun, M. & Greenberg, D.A. (2002). Heparin-Binding Epidermal Growth Factor-Like Growth Factor: Hypoxia-Inducible Expression in Vitro and Stimulation of Neurogenesis in Vitro and in Vivo. *The Journal of Neuroscience*, Vol.22, No.13, pp. 5365-5373, ISSN 1529-2401; 0270-6474
- Jin, K., Sun, Y., Xie, L., Childs, J., Mao, X.O. & Greenberg, D.A. (2004). Post-Ischemic Administration of Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) Reduces Infarct Size and Modifies Neurogenesis After Focal Cerebral Ischemia in the Rat. *Journal of Cerebral Blood Flow and Metabolism*, Vol.24, No.4, pp. 399-408, ISSN 0271-678X
- Jin, K.L., Mao, X.O. & Greenberg, D.A. (2000). Vascular Endothelial Growth Factor: Direct Neuroprotective Effect in in Vitro Ischemia. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.97, No.18, pp. 10242-10247, ISSN 0027-8424

- Johe, K.K., Hazel, T.G., Muller, T., Dugich-Djordjevic, M.M. & McKay, R.D. (1996). Single Factors Direct the Differentiation of Stem Cells from the Fetal and Adult Central Nervous System. *Genes & Development*, Vol.10, No.24, pp. 3129-3140, ISSN 0890-9369
- Joseph D'Ercole, A. & Ye, P. (2008). Expanding the Mind: Insulin-Like Growth Factor I and Brain Development. *Endocrinology*, Vol.149, No.12, pp. 5958-5962, ISSN 0013-7227
- Kaigler, D., Krebsbach, P.H., Polverini, P.J. & Mooney, D.J. (2003). Role of Vascular Endothelial Growth Factor in Bone Marrow Stromal Cell Modulation of Endothelial Cells. *Tissue Engineering*, Vol.9, No.1, pp. 95-103, ISSN 1076-3279
- Kernie, S.G. & Parent, J.M. (2010). Forebrain Neurogenesis After Focal Ischemic and Traumatic Brain Injury. *Neurobiology of Disease*, Vol.37, No.2, pp. 267-274, ISSN 1095-953X; 0969-9961
- Kim, H.J., Lee, J.H. & Kim, S.H. (2010). Therapeutic Effects of Human Mesenchymal Stem Cells on Traumatic Brain Injury in Rats: Secretion of Neurotrophic Factors and Inhibition of Apoptosis. *Journal of Neurotrauma*, Vol.27, No.1, pp. 131-138, ISSN 1557-9042; 0897-7151
- Kinnaird, T., Stabile, E., Burnett, M.S., Lee, C.W., Barr, S., Fuchs, S. & Epstein, S.E. (2004). Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote in Vitro and in Vivo Arteriogenesis through Paracrine Mechanisms. *Circulation Research*, Vol.94, No.5, pp. 678-685, ISSN 1524-4571
- Kopen, G.C., Prockop, D.J. & Phinney, D.G. (1999). Marrow Stromal Cells Migrate Throughout Forebrain and Cerebellum, and they Differentiate into Astrocytes After Injection into Neonatal Mouse Brains. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.96, No.19, pp. 10711-10716, ISSN 0027-8424
- Kortesidis, A., Zannettino, A., Isenmann, S., Shi, S., Lapidot, T. & Gronthos, S. (2005). Stromal-Derived Factor-1 Promotes the Growth, Survival, and Development of Human Bone Marrow Stromal Stem Cells. *Blood*, Vol.105, No.10, pp. 3793-3801, ISSN 0006-4971
- Kosaka, N., Kodama, M., Sasaki, H., Yamamoto, Y., Takeshita, F., Takahama, Y., Sakamoto, H., Kato, T., Terada, M. & Ochiya, T. (2006). FGF-4 Regulates Neural Progenitor Cell Proliferation and Neuronal Differentiation. *The FASEB Journal*, Vol.20, No.9, pp. 1484-1485, ISSN 1530-6860; 0892-6638
- Kumar, R., Yoneda, J., Bucana, C.D. & Fidler, I.J. (1998). Regulation of Distinct Steps of Angiogenesis by Different Angiogenic Molecules. *International Journal of Oncology*, Vol.12, No.4, pp. 749-757, ISSN 1019-6439
- Lai, Y., Sun, Y., Skinner, C.M., Son, E.L., Lu, Z., Tuan, R.S., Jilka, R.L., Ling, J. & Chen, X.D. (2010). Reconstitution of Marrow-Derived Extracellular Matrix Ex Vivo: A Robust Culture System for Expanding Large-Scale Highly Functional Human Mesenchymal Stem Cells. *Stem Cells and Development*, Vol.19, No.7, pp. 1095-1107, ISSN 1557-8534; 1547-3287
- Lazarovici, P., Marcinkiewicz, C. & Lelkes, P.I. (2006). Cross Talk between the Cardiovascular and Nervous Systems: Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor

- (NGF)-Implications in Drug Development. *Current Pharmaceutical Design*, Vol.12, No.21, pp. 2609-2622, ISSN 1381-6128
- Lee, B., Clarke, D., Al Ahmad, A., Kahle, M., Parham, C., Auckland, L., Shaw, C., Fidanboylyu, M., Orr, A.W., Ogunshola, O., Fertala, A., Thomas, S.A. & Bix, G.J. (2011). Perlecan Domain V is Neuroprotective and Proangiogenic Following Ischemic Stroke in Rodents. *The Journal of Clinical Investigation*, Vol.121, No.8, pp. 3005-3023, ISSN 1558-8238; 0021-9738
- Lee, J.S., Hong, J.M., Moon, G.J., Lee, P.H., Ahn, Y.H., Bang, O.Y. & STARTING collaborators. (2010). A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients with Ischemic Stroke. *Stem Cells (Dayton, Ohio)*, Vol.28, No.6, pp. 1099-1106, ISSN 1549-4918; 1066-5099
- Leker, R.R. & Shohami, E. (2002). Cerebral Ischemia and Trauma-Different Etiologies Yet Similar Mechanisms: Neuroprotective Opportunities. *Brain Research. Brain Research Reviews*, Vol.39, No.1, pp. 55-73, ISSN 0165-0173
- Li, J., Zhu, H., Liu, Y., Li, Q., Lu, S., Feng, M., Xu, Y., Huang, L., Ma, C., An, Y., Zhao, R.C., Wang, R. & Qin, C. (2010). Human Mesenchymal Stem Cell Transplantation Protects Against Cerebral Ischemic Injury and Upregulates Interleukin-10 Expression in Macaca fascicularis. *Brain Research*, Vol.1334, pp. 65-72, ISSN 1872-6240; 0006-8993
- Li, J.W., Li, L.L., Chang, L.L., Wang, Z.Y. & Xu, Y. (2009). Stem Cell Factor Protects Against Neuronal Apoptosis by Activating AKT/ERK in Diabetic Mice. *Brazilian Journal of Medical and Biological Research*, Vol.42, No.11, pp. 1044-1049, ISSN 1414-431X; 0100-879X
- Li, Y., Chen, J., Chen, X.G., Wang, L., Gautam, S.C., Xu, Y.X., Katakowski, M., Zhang, L.J., Lu, M., Janakiraman, N. & Chopp, M. (2002). Human Marrow Stromal Cell Therapy for Stroke in Rat: Neurotrophins and Functional Recovery. *Neurology*, Vol.59, No.4, pp. 514-523, ISSN 0028-3878
- Li, Y., Chen, J., Zhang, C.L., Wang, L., Lu, D., Katakowski, M., Gao, Q., Shen, L.H., Zhang, J., Lu, M. & Chopp, M. (2005). Gliosis and Brain Remodeling After Treatment of Stroke in Rats with Marrow Stromal Cells. *Glia*, Vol.49, No.3, pp. 407-417, ISSN 0894-1491
- Li, Y. & Chopp, M. (2009). Marrow Stromal Cell Transplantation in Stroke and Traumatic Brain Injury. *Neuroscience Letters*, Vol.456, No.3, pp. 120-123, ISSN 1872-7972; 0304-3940
- Lipsky, R.H. & Marini, A.M. (2007). Brain-Derived Neurotrophic Factor in Neuronal Survival and Behavior-Related Plasticity. *Annals of the New York Academy of Sciences*, Vol.1122, pp. 130-143, ISSN 0077-8923
- Liu, X.S., Chopp, M., Zhang, R.L., Hozeska-Solgot, A., Gregg, S.C., Buller, B., Lu, M. & Zhang, Z.G. (2009). Angiopoietin 2 Mediates the Differentiation and Migration of Neural Progenitor Cells in the Subventricular Zone After Stroke. *The Journal of Biological Chemistry*, Vol.284, No.34, pp. 22680-22689, ISSN 1083-351X; 0021-9258
- Lopez-Lopez, C., LeRoith, D. & Torres-Aleman, I. (2004). Insulin-Like Growth Factor I is Required for Vessel Remodeling in the Adult Brain. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.101, No.26, pp. 9833-9838, ISSN 0027-8424

- Lu, P., Blesch, A. & Tuszynski, M.H. (2004). Induction of Bone Marrow Stromal Cells to Neurons: Differentiation, Transdifferentiation, Or Artifact? *Journal of Neuroscience Research*, Vol.77, No.2, pp. 174-191, ISSN 0360-4012
- Lu, Y.Z., Lin, C.H., Cheng, F.C. & Hsueh, C.M. (2005). Molecular Mechanisms Responsible for Microglia-Derived Protection of Sprague-Dawley Rat Brain Cells during in Vitro Ischemia. *Neuroscience Letters*, Vol.373, No.2, pp. 159-164, ISSN 0304-3940
- Lum, M., Turbic, A., Mitrovic, B. & Turnley, A.M. (2009). Fibroblast Growth Factor-9 Inhibits Astrocyte Differentiation of Adult Mouse Neural Progenitor Cells. *Journal of Neuroscience Research*, Vol.87, No.10, pp. 2201-2210, ISSN 1097-4547; 0360-4012
- Lykissas, M.G., Batistatou, A.K., Charalabopoulos, K.A. & Beris, A.E. (2007). The Role of Neurotrophins in Axonal Growth, Guidance, and Regeneration. *Current Neurovascular Research*, Vol.4, No.2, pp. 143-151, ISSN 1567-2026
- Ma, M., Ma, Y., Yi, X., Guo, R., Zhu, W., Fan, X., Xu, G., Frey, W.H., 2nd & Liu, X. (2008). Intranasal Delivery of Transforming Growth Factor-beta1 in Mice After Stroke Reduces Infarct Volume and Increases Neurogenesis in the Subventricular Zone. *BMC Neuroscience*, Vol.9, pp. 117, ISSN 1471-2202
- Ma, W., Fitzgerald, W., Liu, Q.Y., O'Shaughnessy, T.J., Maric, D., Lin, H.J., Alkon, D.L. & Barker, J.L. (2004). CNS Stem and Progenitor Cell Differentiation into Functional Neuronal Circuits in Three-Dimensional Collagen Gels. *Experimental Neurology*, Vol.190, No.2, pp. 276-288, ISSN 0014-4886
- Maas, A.I., Roozenbeek, B. & Manley, G.T. (2010). Clinical Trials in Traumatic Brain Injury: Past Experience and Current Developments. *Neurotherapeutics*, Vol.7, No.1, pp. 115-126, ISSN 1878-7479
- Mahmood, A., Lu, D. & Chopp, M. (2004). Marrow Stromal Cell Transplantation After Traumatic Brain Injury Promotes Cellular Proliferation within the Brain. *Neurosurgery*, Vol.55, No.5, pp. 1185-1193, ISSN 1524-4040; 0148-396X
- Mathieu, P., Piantanida, A.P. & Pitossi, F. (2010). Chronic Expression of Transforming Growth Factor-Beta Enhances Adult Neurogenesis. *Neuroimmunomodulation*, Vol.17, No.3, pp. 200-201, ISSN 1423-0216; 1021-7401
- Mehler, M.F., Rozental, R., Dougherty, M., Spray, D.C. & Kessler, J.A. (1993). Cytokine Regulation of Neuronal Differentiation of Hippocampal Progenitor Cells. *Nature*, Vol.362, No.6415, pp. 62-65, ISSN 0028-0836
- Mezey, E., Mayer, B. & Nemeth, K. (2010). Unexpected Roles for Bone Marrow Stromal Cells (Or MSCs): A Real Promise for Cellular, but Not Replacement, Therapy. *Oral Diseases*, Vol.16, No.2, pp. 129-135, ISSN 1601-0825; 1354-523X
- Minamino, K., Adachi, Y., Okigaki, M., Ito, H., Togawa, Y., Fujita, K., Tomita, M., Suzuki, Y., Zhang, Y., Iwasaki, M., Nakano, K., Koike, Y., Matsubara, H., Iwasaka, T., Matsumura, M. & Ikehara, S. (2005). Macrophage Colony-Stimulating Factor (M-CSF), as Well as Granulocyte Colony-Stimulating Factor (G-CSF), Accelerates Neovascularization. *Stem Cells*, Vol.23, No.3, pp. 347-354, ISSN 1066-5099
- Mitsios, N., Gaffney, J., Kumar, P., Krupinski, J., Kumar, S. & Slevin, M. (2006). Pathophysiology of Acute Ischaemic Stroke: An Analysis of Common Signalling Mechanisms and Identification of New Molecular Targets. *Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology*, Vol.73, No.4, pp. 159-175, ISSN 1015-2008

- Mosesson, M.W. (1984). The Role of Fibronectin in monocyte/macrophage Function. *Progress in Clinical and Biological Research*, Vol.154, pp. 155-175, ISSN 0361-7742
- Mudo, G., Bonomo, A., Di Liberto, V., Frinchi, M., Fuxe, K. & Belluardo, N. (2009). The FGF-2/FGFRs Neurotrophic System Promotes Neurogenesis in the Adult Brain. *Journal of Neural Transmission*, Vol.116, No.8, pp. 995-1005, ISSN 1435-1463; 0300-9564
- Munoz-Elias, G., Marcus, A.J., Coyne, T.M., Woodbury, D. & Black, I.B. (2004). Adult Bone Marrow Stromal Cells in the Embryonic Brain: Engraftment, Migration, Differentiation, and Long-Term Survival. *The Journal of Neuroscience*, Vol.24, No.19, pp. 4585-4595, 1529-2401
- Nag, S., Kapadia, A. & Stewart, D.J. (2011). Review: Molecular Pathogenesis of Blood-Brain Barrier Breakdown in Acute Brain Injury. *Neuropathology and Applied Neurobiology*, Vol.37, No.1, pp. 3-23, 1365-2990; 0305-1846
- Nasu-Tada, K., Koizumi, S. & Inoue, K. (2005). Involvement of beta1 Integrin in Microglial Chemotaxis and Proliferation on Fibronectin: Different Regulations by ADP through PKA. *Glia*, Vol.52, No.2, pp. 98-107, ISSN 1098-1136; 0894-1491
- Nauta, A.J. & Fibbe, W.E. (2007). Immunomodulatory Properties of Mesenchymal Stromal Cells. *Blood*, Vol.110, No.10, pp. 3499-3506, ISSN 0006-4971
- Neuhuber, B., Gallo, G., Howard, L., Kostura, L., Mackay, A. & Fischer, I. (2004). Reevaluation of in Vitro Differentiation Protocols for Bone Marrow Stromal Cells: Disruption of Actin Cytoskeleton Induces Rapid Morphological Changes and Mimics Neuronal Phenotype. *Journal of Neuroscience Research*, Vol.77, No.2, pp. 192-204, ISSN 0360-4012
- Neuss, S., Becher, E., Woltje, M., Tietze, L. & Jahnen-Dechent, W. (2004). Functional Expression of HGF and HGF receptor/c-Met in Adult Human Mesenchymal Stem Cells Suggests a Role in Cell Mobilization, Tissue Repair, and Wound Healing. *Stem Cells*, Vol.22, No.3, pp. 405-414, ISSN 1066-5099
- Nishibe, M., Barbay, S., Guggenmos, D. & Nudo, R.J. (2010). Reorganization of Motor Cortex After Controlled Cortical Impact in Rats and Implications for Functional Recovery. *Journal of Neurotrauma*, Vol.27, No.12, pp. 2221-2232, ISSN 1557-9042; 0897-7151
- Nobes, C.D. & Tolkovsky, A.M. (1995). Neutralizing Anti-p21ras Fabs Suppress Rat Sympathetic Neuron Survival Induced by NGF, LIF, CNTF and cAMP. *The European Journal of Neuroscience*, Vol.7, No.2, pp. 344-350, ISSN 0953-816X
- Noonan, D.M., De Lerma Barbaro, A., Vannini, N., Mortara, L. & Albini, A. (2008). Inflammation, Inflammatory Cells and Angiogenesis: Decisions and Indecisions. *Cancer Metastasis Reviews*, Vol.27, No.1, pp. 31-40, ISSN 0167-7659
- Numasaki, M., Fukushi, J., Ono, M., Narula, S.K., Zavodny, P.J., Kudo, T., Robbins, P.D., Tahara, H. & Lotze, M.T. (2003). Interleukin-17 Promotes Angiogenesis and Tumor Growth. *Blood*, Vol.101, No.7, pp. 2620-2627, 0006-4971; 0006-4971
- O'Collins, V.E., Macleod, M.R., Donnan, G.A., Horkey, L.L., van der Worp, B.H. & Howells, D.W. (2006). 1,026 Experimental Treatments in Acute Stroke. *Annals of Neurology*, Vol.59, No.3, pp. 467-477, ISSN 0364-5134
- Oh, J., McCloskey, M.A., Blong, C.C., Bendickson, L., Nilsen-Hamilton, M. & Sakaguchi, D.S. (2010). Astrocyte-Derived Interleukin-6 Promotes Specific Neuronal Differentiation of Neural Progenitor Cells from Adult Hippocampus. *Journal of Neuroscience Research*, Vol.88, No.13, pp. 2798-2809, ISSN 1097-4547; 0360-4012

- Ohab, J.J. & Carmichael, S.T. (2008). Poststroke Neurogenesis: Emerging Principles of Migration and Localization of Immature Neurons. *The Neuroscientist*, Vol.14, No.4, pp. 369-380, ISSN 1073-8584
- Omorì, Y., Honmou, O., Harada, K., Suzuki, J., Houkin, K. & Kocsis, J.D. (2008). Optimization of a Therapeutic Protocol for Intravenous Injection of Human Mesenchymal Stem Cells After Cerebral Ischemia in Adult Rats. *Brain Research*, Vol.1236, pp. 30-38, ISSN 0006-8993
- Onda, T., Honmou, O., Harada, K., Houkin, K., Hamada, H. & Kocsis, J.D. (2008). Therapeutic Benefits by Human Mesenchymal Stem Cells (hMSCs) and Ang-1 Gene-Modified hMSCs After Cerebral Ischemia. *Journal of Cerebral Blood Flow and Metabolism*, Vol.28, No.2, pp. 329-340, ISSN 0271-678X
- Opanashuk, L.A., Mark, R.J., Porter, J., Damm, D., Mattson, M.P. & Seroogy, K.B. (1999). Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Hippocampus: Modulation of Expression by Seizures and Anti-Excitotoxic Action. *The Journal of Neuroscience*, Vol.19, No.1, pp. 133-146, ISSN 0270-6474
- Parr, A.M., Tator, C.H. & Keating, A. (2007). Bone Marrow-Derived Mesenchymal Stromal Cells for the Repair of Central Nervous System Injury. *Bone Marrow Transplantation*, Vol.40, No.7, pp. 609-619, ISSN 0268-3369
- Pavlichenko, N., Sokolova, I., Vijde, S., Shvedova, E., Alexandrov, G., Krouglyakov, P., Fedotova, O., Gilerovich, E.G., Polyntsev, D.G. & Otellin, V.A. (2008). Mesenchymal Stem Cells Transplantation could be Beneficial for Treatment of Experimental Ischemic Stroke in Rats. *Brain Research*, Vol.1233, pp. 203-213, ISSN 0006-8993
- Perris, R. & Perissinotto, D. (2000). Role of the Extracellular Matrix during Neural Crest Cell Migration. *Mechanisms of Development*, Vol.95, No.1-2, pp. 3-21, ISSN 0925-4773
- Phinney, D.G. & Prockop, D.J. (2007). Concise Review: Mesenchymal stem/multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair--Current Views. *Stem Cells*, Vol.25, No.11, pp. 2896-2902, ISSN 1549-4918; 1066-5099
- Pires Neto, M.A., Braga-de-Souza, S. & Lent, R. (1999). Extracellular Matrix Molecules Play Diverse Roles in the Growth and Guidance of Central Nervous System Axons. *Brazilian Journal of Medical and Biological Research*, Vol.32, No.5, pp. 633-638, ISSN 0100-879X
- Ponte, A.L., Marais, E., Gallay, N., Langonne, A., Delorme, B., Herault, O., Charbord, P. & Domenech, J. (2007). The in Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities. *Stem Cells*, Vol.25, No.7, pp. 1737-1745, ISSN 1066-5099
- Potapova, I.A., Gaudette, G.R., Brink, P.R., Robinson, R.B., Rosen, M.R., Cohen, I.S. & Doronin, S.V. (2007). Mesenchymal Stem Cells Support Migration, Extracellular Matrix Invasion, Proliferation, and Survival of Endothelial Cells in Vitro. *Stem Cells*, Vol.25, No.7, pp. 1761-1768, ISSN 1066-5099
- Potian, J.A., Aviv, H., Ponzio, N.M., Harrison, J.S. & Rameshwar, P. (2003). Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination between Cellular Responses to Alloantigens and Recall Antigens. *Journal of Immunology*, Vol.171, No.7, pp. 3426-3434, ISSN 0022-1767

- Properzi, F., Asher, R.A. & Fawcett, J.W. (2003). Chondroitin Sulphate Proteoglycans in the Central Nervous System: Changes and Synthesis After Injury. *Biochemical Society Transactions*, Vol.31, No.2, pp. 335-336, ISSN 1470-8752; 0300-5127
- Qin, L., Kim, E., Ratan, R., Lee, F.S. & Cho, S. (2011). Genetic Variant of BDNF (Val66Met) Polymorphism Attenuates Stroke-Induced Angiogenic Responses by Enhancing Anti-Angiogenic Mediator CD36 Expression. *The Journal of Neuroscience*, Vol.31, No.2, pp. 775-783, ISSN 1529-2401; 0270-6474
- Robinson, A.P., Foraker, J.E., Ylostalo, J. & Prockop, D.J. (2011). Human stem/progenitor Cells from Bone Marrow Enhance Glial Differentiation of Rat Neural Stem Cells: A Role for Transforming Growth Factor Beta and Notch Signaling. *Stem Cells and Development*, Vol.20, No.2, pp. 289-300, ISSN 1557-8534; 1547-3287
- Robinson, S., Tani, M., Strieter, R.M., Ransohoff, R.M. & Miller, R.H. (1998). The Chemokine Growth-Regulated Oncogene-Alpha Promotes Spinal Cord Oligodendrocyte Precursor Proliferation. *The Journal of Neuroscience*, Vol.18, No.24, pp. 10457-10463, ISSN 0270-6474
- Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Adams, R.J., Berry, J.D., Brown, T.M., Carnethon, M.R., Dai, S., de Simone, G., Ford, E.S., Fox, C.S., Fullerton, H.J., Gillespie, C., Greenlund, K.J., Hailpern, S.M., Heit, J.A., Ho, P.M., Howard, V.J., Kissela, B.M., Kittner, S.J., Lackland, D.T., Lichtman, J.H., Lisabeth, L.D., Makuc, D.M., Marcus, G.M., Marelli, A., Matchar, D.B., McDermott, M.M., Meigs, J.B., Moy, C.S., Mozaffarian, D., Mussolino, M.E., Nichol, G., Paynter, N.P., Rosamond, W.D., Sorlie, P.D., Stafford, R.S., Turan, T.N., Turner, M.B., Wong, N.D., Wylie-Rosett, J. & American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (2011). Heart Disease and Stroke Statistics--2011 Update: A Report from the American Heart Association. *Circulation*, Vol.123, No.4, pp. e18-e209, ISSN 1524-4539; 0009-7322
- Sabo, J.K., Kilpatrick, T.J. & Cate, H.S. (2009). Effects of Bone Morphogenic Proteins on Neural Precursor Cells and Regulation during Central Nervous System Injury. *Neuro-Signals*, Vol.17, No.4, pp. 255-264, ISSN 1424-8638; 1424-862X
- Sadohara, T., Sugahara, K., Urashima, Y., Terasaki, H. & Lyama, K. (2001). Keratinocyte Growth Factor Prevents Ischemia-Induced Delayed Neuronal Death in the Hippocampal CA1 Field of the Gerbil Brain. *Neuroreport*, Vol.12, No.1, pp. 71-76, ISSN 0959-4965
- Sakai, T., Johnson, K.J., Murozono, M., Sakai, K., Magnuson, M.A., Wieloch, T., Cronberg, T., Isshiki, A., Erickson, H.P. & Fassler, R. (2001). Plasma Fibronectin Supports Neuronal Survival and Reduces Brain Injury Following Transient Focal Cerebral Ischemia but is Not Essential for Skin-Wound Healing and Hemostasis. *Nature Medicine*, Vol.7, No.3, pp. 324-30., ISSN 1546-170X; 1078-8956
- Sanchez-Ramos, J., Song, S., Cardozo-Pelaez, F., Hazzi, C., Stedeford, T., Willing, A., Freeman, T.B., Saporta, S., Janssen, W., Patel, N., Cooper, D.R. & Sanberg, P.R. (2000). Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in Vitro. *Experimental Neurology*, Vol.164, No.2, pp. 247-256, ISSN 0014-4886
- Schabitz, W.R., Kollmar, R., Schwaninger, M., Juettler, E., Bardutzky, J., Scholzke, M.N., Sommer, C. & Schwab, S. (2003). Neuroprotective Effect of Granulocyte Colony-

- Stimulating Factor After Focal Cerebral Ischemia. *Stroke*, Vol.34, No.3, pp. 745-751, ISSN 1524-4628; 0039-2499
- Schabitz, W.R., Steigleder, T., Cooper-Kuhn, C.M., Schwab, S., Sommer, C., Schneider, A. & Kuhn, H.G. (2007). Intravenous Brain-Derived Neurotrophic Factor Enhances Poststroke Sensorimotor Recovery and Stimulates Neurogenesis. *Stroke*, Vol.38, No.7, pp. 2165-2172, ISSN 1524-4628; 0039-2499
- Schinkothe, T., Bloch, W. & Schmidt, A. (2008). In Vitro Secreting Profile of Human Mesenchymal Stem Cells. *Stem Cells and Development*, Vol.17, No.1, pp. 199-206, ISSN 1547-3287
- Schmidt, A., Ladage, D., Schinkothe, T., Klausmann, U., Ulrichs, C., Klinz, F.J., Brixius, K., Arnhold, S., Desai, B., Mehlhorn, U., Schwinger, R.H., Staib, P., Addicks, K. & Bloch, W. (2006). Basic Fibroblast Growth Factor Controls Migration in Human Mesenchymal Stem Cells. *Stem Cells*, Vol.24, No.7, pp. 1750-1758, ISSN 1066-5099
- Schneider, A., Kruger, C., Steigleder, T., Weber, D., Pitzer, C., Laage, R., Aronowski, J., Maurer, M.H., Gassler, N., Mier, W., Hasselblatt, M., Kollmar, R., Schwab, S., Sommer, C., Bach, A., Kuhn, H.G. & Schabitz, W.R. (2005). The Hematopoietic Factor G-CSF is a Neuronal Ligand that Counteracts Programmed Cell Death and Drives Neurogenesis. *The Journal of Clinical Investigation*, Vol.115, No.8, pp. 2083-2098, ISSN 0021-9738
- Sehara, Y., Hayashi, T., Deguchi, K., Zhang, H., Tsuchiya, A., Yamashita, T., Lukic, V., Nagai, M., Kamiya, T. & Abe, K. (2007). Potentiation of Neurogenesis and Angiogenesis by G-CSF After Focal Cerebral Ischemia in Rats. *Brain Research*, Vol.1151, pp. 142-149, ISSN 0006-8993
- Shang, J., Deguchi, K., Ohta, Y., Liu, N., Zhang, X., Tian, F., Yamashita, T., Ikeda, Y., Matsuura, T., Funakoshi, H., Nakamura, T. & Abe, K. (2011). Strong Neurogenesis, Angiogenesis, Synaptogenesis, and Antifibrosis of Hepatocyte Growth Factor in Rats Brain After Transient Middle Cerebral Artery Occlusion. *Journal of Neuroscience Research*, Vol.89, No.1, pp. 86-95, ISSN 1097-4547; 0360-4012
- Shen, L.H., Li, Y., Gao, Q., Savant-Bhonsale, S. & Chopp, M. (2008). Down-Regulation of Neurocan Expression in Reactive Astrocytes Promotes Axonal Regeneration and Facilitates the Neurorestorative Effects of Bone Marrow Stromal Cells in the Ischemic Rat Brain. *Glia*, Vol.56, No.16, pp. 1747-1754, ISSN 1098-1136; 0894-1491
- Shen, Y., Inoue, N. & Heese, K. (2010). Neurotrophin-4 (ntf4) Mediates Neurogenesis in Mouse Embryonic Neural Stem Cells through the Inhibition of the Signal Transducer and Activator of Transcription-3 (stat3) and the Modulation of the Activity of Protein Kinase B. *Cellular and Molecular Neurobiology*, Vol.30, No.6, pp. 909-916, ISSN 1573-6830; 0272-4340
- Shibuya, M. (2009). Brain Angiogenesis in Developmental and Pathological Processes: Therapeutic Aspects of Vascular Endothelial Growth Factor. *The FEBS Journal*, Vol.276, No.17, pp. 4636-4643, ISSN 1742-4658; 1742-464X
- Shimamura, M., Sato, N., Waguri, S., Uchiyama, Y., Hayashi, T., Iida, H., Nakamura, T., Ogihara, T., Kaneda, Y. & Morishita, R. (2006). Gene Transfer of Hepatocyte Growth Factor Gene Improves Learning and Memory in the Chronic Stage of Cerebral Infarction. *Hypertension*, Vol.47, No.4, pp. 742-751, ISSN 1524-4563

- Shimazaki, T., Shingo, T. & Weiss, S. (2001). The Ciliary Neurotrophic factor/leukemia Inhibitory factor/gp130 Receptor Complex Operates in the Maintenance of Mammalian Forebrain Neural Stem Cells. *The Journal of Neuroscience*, Vol.21, No.19, pp. 7642-7653, ISSN 1529-2401; 0270-6474
- Shirakura, M., Inoue, M., Fujikawa, S., Washizawa, K., Komaba, S., Maeda, M., Watabe, K., Yoshikawa, Y. & Hasegawa, M. (2004). Postischemic Administration of Sendai Virus Vector Carrying Neurotrophic Factor Genes Prevents Delayed Neuronal Death in Gerbils. *Gene Therapy*, Vol.11, No.9, pp. 784-790, ISSN 0969-7128
- Shyu, W.C., Lin, S.Z., Yang, H.I., Tzeng, Y.S., Pang, C.Y., Yen, P.S. & Li, H. (2004). Functional Recovery of Stroke Rats Induced by Granulocyte Colony-Stimulating Factor-Stimulated Stem Cells. *Circulation*, Vol.110, No.13, pp. 1847-1854, ISSN 1524-4539; 0009-7322
- Smadja, D.M., d'Audigier, C., Weiswald, L.B., Badoual, C., Dangles-Marie, V., Mauge, L., Evrard, S., Laurendeau, I., Lallemand, F., Germain, S., Grelac, F., Dizier, B., Vidaud, M., Bièche, I. & Gaussem, P. (2010). The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential. *Arteriosclerosis, thrombosis, and vascular biology*, Vol.30, No.12, pp. 2544-2552, ISSN 1079-5642; 1524-4636
- Solaroglu, I., Tsubokawa, T., Cahill, J. & Zhang, J.H. (2006). Anti-Apoptotic Effect of Granulocyte-Colony Stimulating Factor After Focal Cerebral Ischemia in the Rat. *Neuroscience*, Vol.143, No.4, pp. 965-974, ISSN 0306-4522
- Son, B.R., Marquez-Curtis, L.A., Kucia, M., Wysoczynski, M., Turner, A.R., Ratajczak, J., Ratajczak, M.Z. & Janowska-Wieczorek, A. (2006). Migration of Bone Marrow and Cord Blood Mesenchymal Stem Cells in Vitro is Regulated by Stromal-Derived Factor-1-CXCR4 and Hepatocyte Growth Factor-c-Met Axes and Involves Matrix Metalloproteinases. *Stem Cells*, Vol.24, No.5, pp. 1254-1264, ISSN 1066-5099
- Sottile, J. (2004). Regulation of Angiogenesis by Extracellular Matrix. *Biochimica Et Biophysica Acta*, Vol.1654, No.1, pp. 13-22, ISSN 0006-3002
- Suarez-Monteaugudo, C., Hernandez-Ramirez, P., Alvarez-Gonzalez, L., Garcia-Maeso, I., de la Cuetara-Bernal, K., Castillo-Diaz, L., Bringas-Vega, M.L., Martinez-Aching, G., Morales-Chacon, L.M., Baez-Martin, M.M., Sanchez-Catasus, C., Carballo-Barreda, M., Rodriguez-Rojas, R., Gomez-Fernandez, L., Alberti-Amador, E., Macias-Abraham, C., Balea, E.D., Rosales, L.C., Del Valle Perez, L., Ferrer, B.B., Gonzalez, R.M. & Bergado, J.A. (2009). Autologous Bone Marrow Stem Cell Neurotransplantation in Stroke Patients. an Open Study. *Restorative Neurology and Neuroscience*, Vol.27, No.3, pp. 151-161, ISSN 0922-6028
- Sugiura, S., Lahav, R., Han, J., Kou, S.Y., Banner, L.R., de Pablo, F. & Patterson, P.H. (2000). Leukaemia Inhibitory Factor is Required for Normal Inflammatory Responses to Injury in the Peripheral and Central Nervous Systems in Vivo and is Chemotactic for Macrophages in Vitro. *The European Journal of Neuroscience*, Vol.12, No.2, pp. 457-466, ISSN 0953-816X
- Sun, L., Hui, A.M., Su, Q., Vortmeyer, A., Kotliarov, Y., Pastorino, S., Passaniti, A., Menon, J., Walling, J., Bailey, R., Rosenblum, M., Mikkelsen, T. & Fine, H.A. (2006). Neuronal and Glioma-Derived Stem Cell Factor Induces Angiogenesis within the Brain. *Cancer Cell*, Vol.9, No.4, pp. 287-300, ISSN 1535-6108


- Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X.O., Logvinova, A. & Greenberg, D.A. (2003). VEGF-Induced Neuroprotection, Neurogenesis, and Angiogenesis After Focal Cerebral Ischemia. *The Journal of Clinical Investigation*, Vol.111, No.12, pp. 1843-1851, ISSN 0021-9738
- Swartz, K.R., Liu, F., Sewell, D., Schochet, T., Campbell, I., Sandor, M. & Fabry, Z. (2001). Interleukin-6 Promotes Post-Traumatic Healing in the Central Nervous System. *Brain Research*, Vol.896, No.1-2, pp. 86-95, ISSN 0006-8993
- Taga, T. & Fukuda, S. (2005). Role of IL-6 in the Neural Stem Cell Differentiation. *Clinical Reviews in Allergy & Immunology*, Vol.28, No.3, pp. 249-256, ISSN 1080-0549
- Tan, H.K., Heywood, D., Ralph, G.S., Bienemann, A., Baker, A.H. & Uney, J.B. (2003). Tissue Inhibitor of Metalloproteinase 1 Inhibits Excitotoxic Cell Death in Neurons. *Molecular and Cellular Neurosciences*, Vol.22, No.1, pp. 98-106, ISSN 1044-7431
- Tate, C.C., Fonck, C., McGrogan, M. & Case, C.C. (2010). Human Mesenchymal Stromal Cells and their Derivative, SB623 Cells, Rescue Neural Cells via Trophic Support Following in Vitro Ischemia. *Cell Transplantation*, Vol.19, No.8, pp. 973-984, ISSN 1555-3892; 0963-6897
- Tate, C.C., Garcia, A.J. & LaPlaca, M.C. (2007). Plasma Fibronectin is Neuroprotective Following Traumatic Brain Injury. *Experimental Neurology*, Vol.207, No.1, pp. 13-22, ISSN 0014-4886
- Tate, M.C., Garcia, A.J., Keselowsky, B.G., Schumm, M.A., Archer, D.R. & LaPlaca, M.C. (2004). Specific beta1 Integrins Mediate Adhesion, Migration, and Differentiation of Neural Progenitors Derived from the Embryonic Striatum. *Molecular and Cellular Neuroscience*, Vol.27, No.1, pp. 22-31, ISSN 1095-9327; 1044-7431
- Terauchi, A., Johnson-Venkatesh, E.M., Toth, A.B., Javed, D., Sutton, M.A. & Umemori, H. (2010). Distinct FGFs Promote Differentiation of Excitatory and Inhibitory Synapses. *Nature*, Vol.465, No.7299, pp. 783-787, ISSN 1476-4687; 0028-0836
- Testaz, S. & Duband, J.L. (2001). Central Role of the alpha4beta1 Integrin in the Coordination of Avian Truncal Neural Crest Cell Adhesion, Migration, and Survival. *Developmental dynamics*, Vol.222, No.2, pp. 127-140, ISSN 1097-0177; 1058-8388
- Thored, P., Arvidsson, A., Cacci, E., Ahlenius, H., Kallur, T., Darsalia, V., Ekdahl, C.T., Kokaia, Z. & Lindvall, O. (2006). Persistent Production of Neurons from Adult Brain Stem Cells during Recovery After Stroke. *Stem Cells (Dayton, Ohio)*, Vol.24, No.3, pp. 739-747, ISSN 1066-5099
- Vana, A.C., Flint, N.C., Harwood, N.E., Le, T.Q., Fruttiger, M. & Armstrong, R.C. (2007). Platelet-Derived Growth Factor Promotes Repair of Chronically Demyelinated White Matter. *Journal of Neuropathology and Experimental Neurology*, Vol.66, No.11, pp. 975-988, ISSN 0022-3069
- Vasse, M., Pourtau, J., Trochon, V., Muraine, M., Vannier, J.P., Lu, H., Soria, J. & Soria, C. (1999). Oncostatin M Induces Angiogenesis in Vitro and in Vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, Vol.19, No.8, pp. 1835-1842, ISSN 1079-5642

- Villoslada, P. & Genain, C.P. (2004). Role of Nerve Growth Factor and Other Trophic Factors in Brain Inflammation. *Progress in Brain Research*, Vol.146, pp. 403-414, ISSN 0079-6123
- Vincent, V.A., Robinson, C.C., Simsek, D. & Murphy, G.M. (2002). Macrophage Colony Stimulating Factor Prevents NMDA-Induced Neuronal Death in Hippocampal Organotypic Cultures. *Journal of Neurochemistry*, Vol.82, No.6, pp. 1388-1397, ISSN 0022-3042
- Wang, L., Li, Y., Chen, X., Chen, J., Gautam, S.C., Xu, Y. & Chopp, M. (2002). MCP-1, MIP-1, IL-8 and Ischemic Cerebral Tissue Enhance Human Bone Marrow Stromal Cell Migration in Interface Culture. *Hematology*, Vol.7, No.2, pp. 113-117, ISSN 1024-5332
- Wang, M., Crisostomo, P.R., Herring, C., Meldrum, K.K. & Meldrum, D.R. (2006). Human Progenitor Cells from Bone Marrow Or Adipose Tissue Produce VEGF, HGF, and IGF-I in Response to TNF by a p38 MAPK-Dependent Mechanism. *American Journal of Physiology.Regulatory, Integrative and Comparative Physiology*, Vol.291, No.4, pp. R880-4, ISSN 0363-6119
- Wang, Y., Jin, K., Mao, X.O., Xie, L., Banwait, S., Marti, H.H. & Greenberg, D.A. (2007a). VEGF-Overexpressing Transgenic Mice show Enhanced Post-Ischemic Neurogenesis and Neuromigration. *Journal of Neuroscience Research*, Vol.85, No.4, pp. 740-747, ISSN 0360-4012
- Wang, Y.Q., Guo, X., Qiu, M.H., Feng, X.Y. & Sun, F.Y. (2007b). VEGF Overexpression Enhances Striatal Neurogenesis in Brain of Adult Rat After a Transient Middle Cerebral Artery Occlusion. *Journal of Neuroscience Research*, Vol.85, No.1, pp. 73-82, ISSN 0360-4012
- Weiss, T.W., Samson, A.L., Niego, B., Daniel, P.B. & Medcalf, R.L. (2006). Oncostatin M is a Neuroprotective Cytokine that Inhibits Excitotoxic Injury in Vitro and in Vivo. *The FASEB Journal*, Vol.20, No.13, pp. 2369-2371, ISSN 1530-6860; 0892-6638
- Wells, W.A. (2002). Is Transdifferentiation in Trouble? *The Journal of Cell Biology*, Vol.157, No.1, pp. 15-18, ISSN 0021-9525
- Widera, D., Holtkamp, W., Entschladen, F., Niggemann, B., Zanker, K., Kaltschmidt, B. & Kaltschmidt, C. (2004). MCP-1 Induces Migration of Adult Neural Stem Cells. *European Journal of Cell Biology*, Vol.83, No.8, pp. 381-387, ISSN 0171-9335
- Wilkins, A., Chandran, S. & Compston, A. (2001). A Role for Oligodendrocyte-Derived IGF-1 in Trophic Support of Cortical Neurons. *Glia*, Vol.36, No.1, pp. 48-57, ISSN 0894-1491
- Woodbury, D., Schwarz, E.J., Prockop, D.J. & Black, I.B. (2000). Adult Rat and Human Bone Marrow Stromal Cells Differentiate into Neurons. *Journal of Neuroscience Research*, Vol.61, No.4, pp. 364-370, ISSN 0360-4012
- Wright, D.W., Kellermann, A.L., Hertzberg, V.S., Clark, P.L., Frankel, M., Goldstein, F.C., Salomone, J.P., Dent, L.L., Harris, O.A., Ander, D.S., Lowery, D.W., Patel, M.M., Denson, D.D., Gordon, A.B., Wald, M.M., Gupta, S., Hoffman, S.W. & Stein, D.G. (2007). ProTECT: A Randomized Clinical Trial of Progesterone for Acute Traumatic Brain Injury. *Annals of Emergency Medicine*, Vol.49, No.4, pp. 391-402, 402.e1-2, ISSN 1097-6760

- Xin, H., Li, Y., Shen, L.H., Liu, X., Wang, X., Zhang, J., Pourabdollah-Nejad, D.S., Zhang, C., Zhang, L., Jiang, H., Zhang, Z.G. & Chopp, M. (2010). Increasing tPA Activity in Astrocytes Induced by Multipotent Mesenchymal Stromal Cells Facilitate Neurite Outgrowth After Stroke in the Mouse. *PLoS One*, Vol.5, No.2, pp. e9027, ISSN 1932-6203
- Xiong, Y., Qu, C., Mahmood, A., Liu, Z., Ning, R., Li, Y., Kaplan, D.L., Schallert, T. & Chopp, M. (2009). Delayed Transplantation of Human Marrow Stromal Cell-Seeded Scaffolds Increases Transcallosal Neural Fiber Length, Angiogenesis, and Hippocampal Neuronal Survival and Improves Functional Outcome After Traumatic Brain Injury in Rats. *Brain Research*, Vol.1263, pp. 183-191, ISSN 1872-6240; 0006-8993
- Yabe, T., Samuels, I. & Schwartz, J.P. (2002). Bone Morphogenetic Proteins BMP-6 and BMP-7 have Differential Effects on Survival and Neurite Outgrowth of Cerebellar Granule Cell Neurons. *Journal of Neuroscience Research*, Vol.68, No.2, pp. 161-168, ISSN 0360-4012
- Yamada, M., Tanabe, K., Wada, K., Shimoke, K., Ishikawa, Y., Ikeuchi, T., Koizumi, S. & Hatanaka, H. (2001). Differences in Survival-Promoting Effects and Intracellular Signaling Properties of BDNF and IGF-1 in Cultured Cerebral Cortical Neurons. *Journal of Neurochemistry*, Vol.78, No.5, pp. 940-951, ISSN 0022-3042
- Yan, Y.P., Sailor, K.A., Lang, B.T., Park, S.W., Vemuganti, R. & Dempsey, R.J. (2007). Monocyte Chemoattractant Protein-1 Plays a Critical Role in Neuroblast Migration After Focal Cerebral Ischemia. *Journal of Cerebral Blood Flow and Metabolism*, Vol.27, No.6, pp. 1213-1224, ISSN 0271-678X
- Yi, J.J., Barnes, A.P., Hand, R., Polleux, F. & Ehlers, M.D. (2010). TGF-Beta Signaling Specifies Axons during Brain Development. *Cell*, Vol.142, No.1, pp. 144-157, ISSN 1097-4172; 0092-8674
- Yoo, S.W., Kim, S.S., Lee, S.Y., Lee, H.S., Kim, H.S., Lee, Y.D. & Suh-Kim, H. (2008). Mesenchymal Stem Cells Promote Proliferation of Endogenous Neural Stem Cells and Survival of Newborn Cells in a Rat Stroke Model. *Experimental & Molecular Medicine*, Vol.40, No.4, pp. 387-397, ISSN 1226-3613
- Yung, H.S., Lai, K.H., Chow, K.B., Ip, N.Y., Tsim, K.W., Wong, Y.H., Wu, Z. & Wise, H. (2010). Nerve Growth Factor-Induced Differentiation of PC12 Cells is Accompanied by Elevated Adenylyl Cyclase Activity. *Neuro-Signals*, Vol.18, No.1, pp. 32-42, ISSN 1424-8638; 1424-862X
- Zanier, E.R., Montinaro, M., Vigano, M., Villa, P., Fumagalli, S., Pischutta, F., Longhi, L., Leoni, M.L., Rebulli, P., Stocchetti, N., Lazzari, L. & Simoni, M.G. (2011). Human Umbilical Cord Blood Mesenchymal Stem Cells Protect Mice Brain After Trauma. *Critical Care Medicine*, ISSN 1530-0293; 0090-3493
- Zechel, S., Werner, S., Unsicker, K. & von Bohlen und Halbach, O. (2010). Expression and Functions of Fibroblast Growth Factor 2 (FGF-2) in Hippocampal Formation. *The Neuroscientist*, Vol.16, No.4, pp. 357-373, ISSN 1089-4098; 1073-8584
- Zhang, Z.X., Guan, L.X., Zhang, K., Zhang, Q. & Dai, L.J. (2008). A Combined Procedure to Deliver Autologous Mesenchymal Stromal Cells to Patients with Traumatic Brain Injury. *Cytotherapy*, Vol.10, No.2, pp. 134-139, ISSN 1477-2566; 1465-3249

- Zhao, L.R., Singhal, S., Duan, W.M., Mehta, J. & Kessler, J.A. (2007). Brain Repair by Hematopoietic Growth Factors in a Rat Model of Stroke. *Stroke*, Vol.38, No.9, pp. 2584-2591, 1524-4628; 0039-2499
- Zhong, C., Qin, Z., Zhong, C.J., Wang, Y. & Shen, X.Y. (2003). Neuroprotective Effects of Bone Marrow Stromal Cells on Rat Organotypic Hippocampal Slice Culture Model of Cerebral Ischemia. *Neuroscience Letters*, Vol.342, No.1-2, pp. 93-96, ISSN 0304-3940
- Zhu, W., Cheng, S., Xu, G., Ma, M., Zhou, Z., Liu, D. & Liu, X. (2011). Intranasal Nerve Growth Factor Enhances Striatal Neurogenesis in Adult Rats with Focal Cerebral Ischemia. *Drug Delivery*, Vol.18, No.5, pp. 338-343, ISSN 1521-0464; 1071-7544

IntechOpen



Advanced Topics in Neurological Disorders

Edited by Dr Ken-Shiung Chen

ISBN 978-953-51-0303-5

Hard cover, 242 pages

Publisher InTech

Published online 16, March, 2012

Published in print edition March, 2012

This book presents recent advances in the field of Neurological disorders research. It consists of 9 chapters encompassing a wide range of areas including bioengineering, stem cell transplantation, gene therapy, proteomic analysis, alternative treatment and neuropsychiatry analysis. It highlights the development of multiple discipline approaches in neurological researches. The book brings together leading researchers in neurological disorders and it presents an essential reference for researchers working in the neurological disorders, as well as for students and industrial users who are interested in current developments in neurological researches.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Ciara C. Tate and Casey C. Case (2012). Mesenchymal Stromal Cells to Treat Brain Injury, Advanced Topics in Neurological Disorders, Dr Ken-Shiung Chen (Ed.), ISBN: 978-953-51-0303-5, InTech, Available from: <http://www.intechopen.com/books/advanced-topics-in-neurological-disorders/mesenchymal-stromal-cells-to-treat-brain-injury>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen